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Abstract
Malaria is still an epidemic in many parts of the world—about 220 million people are still
infected with malaria worldwide and about 700 thousand people die from this disease per
year. Most of the drugs used to treat malaria work well if they are used as required and
they contain the right amounts of the active ingredient; however, it is estimated that more
than 10% of drugs traded worldwide are counterfeits including 38% to 53% of
antimalarial tablets produced in China and India. Due to the lack of data covering the
extent of counterfeit antimalarial drugs in Ghana, the purpose of this quantitative study
was to determine the percentage of counterfeit antimalarial drugs sold in Ghana by
assessing the amounts of the 2 most common antimalarial drugs, artemether (ATMT) and
lumefantrine (LMFT) sold in Ghana retail outlets. These drugs were purchased from
retail outlets in Ghana and analyses at the Mayo Clinic Pharmacology core lab
(Rochester, MN). The quality of the drugs were characterized by comparing the actual
amount of ATMT & LMFT in each tablet to the expected amount. Using explanatory
theory along with dose response-response occupancy theory, the researcher addressed
quantitative solutions to questions related to the percentage and distribution of counterfeit
ATMT and LMFT tablets. The results revealed that overall 20% of the drugs are
counterfeit; this is not dependent on the location or kind of outlet but rather depends on
whether the tablets were imported or locally manufactured and whether the tablets had a
pedigree scratch panel. This study provides a better understanding of how much
antimalarial medication is counterfeit in Ghana, which will aid interventions to minimize
the adverse effects of counterfeit antimalarial medication in Ghana.
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Chapter 1: Introduction to the Study
About 220 million people are infected with malaria worldwide and thousands of
people die from it yearly (Nadjm & Behrens, 2012; World Health Organization [WHO],
2013). The prevalence and mortality rate in sub-Saharan countries related to malaria is
very high, and the rate of deaths for children from these countries is worse. Malaria is
caused by parasites called plasmodium sp. (Zhou et al., 2014), which use mosquitos as
vectors for transmission to humans. Malaria eradication and treatment has been based on
the different stages of the life cycle of the plasmodium parasite. Malaria can be treated
with several drugs, and a majority of these drugs work well if used appropriately and they
contain the right amounts of the active ingredient. It is believed that a high percentage of
these drugs may be counterfeit in Ghana, especially those imported from Southeast Asia
(Amin, Snow, & Kokwaro, 2006). At this time, little is known about how much of these
medications are fake. I addressed the counterfeit problem by empirically finding out how
much antimalarial medication is counterfeit.
Background of the Study
Malaria has been in existence and has been well known for over 2,000 years, but a
majority of discoveries regarding malaria happened in late 19th century. Several Nobel
Laureates made discoveries, including Laveran, who discovered the parasite in 1880, and
Ross, who discovered that malaria is transmitted by mosquitos in 1897 (Rajakumar &
Weisse, 1999). At the turn of the 20th century, several public health departments
including the United States Public Health Service (USPHS) began trying to find ways to
treat and eradicate malaria (Centers for Disease Control and Prevention [CDC], 2009).
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This resulted in the discovery of Chloroquine as an effective drug for treating malaria,
while Dichloro-diphenyl-trichloroethane (DDT), an insecticide, was used to control and
eradicate malaria in the US and most western countries (Roberts, Laughlin, Hsheih, &
Legters, 1997). Eradication efforts were very successful in many countries due to the
efforts of the CDC, which started as the Communicable Disease Center as a part of
malarial control and eradication centers in the US (CDC, 2009); however, sub-Saharan
countries were not part of efforts for malaria eradication. Malaria is still an epidemic in
sub-Saharan countries and a majority of the region’s population die yearly from this
disease (Nadjm & Behrens, 2012; WHO, 2013). About one-third of 100 countries
worldwide suffer from a high mortality rate due to malaria, and more than 95% of these
countries are in sub-Saharan Africa. Ghana, like most of developing sub-Saharan
countries, is still struggling with challenges with basic health care. The lack of effective
health care makes the system very vulnerable and easy for counterfeit medication to
infiltrate the market; over 100,000 deaths per year in Africa are due to counterfeit
medication (WHO, 2014). In recent years, there has been some coverage about
counterfeit antimalarial drugs in Ghana because it directly affected s politician (Daily
Guide, 2013). It is believed that majority of the counterfeit medication comes from South
East Asia (Bate & Hess, 2010), but the extent of counterfeit medication in Ghana is not
known except as described in a few publications and pilot studies (Asuamah, OwusuPrempeh, & Antwi-Boateng, 2013; Bate & Hess, 2010). This study will make up for this
lack of research by describing quantitatively the extent of antimalarial medication in
Ghana.
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Statement of the Problem
Most information on the percentage of counterfeit drugs in the sub-Saharan
African region is speculative or based on anecdotal evidence; there has not been an
extensive study on the whole country that has empirically determined the percentage of
counterfeit antimalarial medication in the Ghana (Asuamah et al., 2013). This study will
fill this gap in literature to address potential for intervention. The two most commonly
used antimalarial medication in this region are artemether (ATMT) and lumefantrine
(LMFT) (Lozano et al., 2012). This study empirically determined the percent of
antimalarial medication using ATMT and LMFT that is counterfeit in pharmaceutical
retail outlets in Ghana.
Purpose of the Study
The purpose of this quantitative study was to explore the extent of antimalarial
counterfeiting by looking at the percentage of ATMT and LMFT in drugs sold in retail
outlets in Ghana that is counterfeit. Fake drugs pose three direct threats to patients:
failure to provide effective treatments, which is estimated to cause thousands of deaths
per year; adulteration with toxic chemicals that leads to fatalities; and substandard drugs
that expose the parasites to sublethal doses, which can cause them to develop a resistance
to the medications (Attaran et al., 2012). To reverse the trend of fake and substandard
drugs, we need an understanding of the extent of counterfeit medication in Ghana. With
this understanding, we can develop proper interventions to potentially minimize the
adverse effects of counterfeit antimalarial medication in Ghana. One covariate I assessed
was the cost of the antimalarial medications. Other variables that I assessed will include
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the differences between pharmacies and licensed chemical stores and geographical
implications on the percent of counterfeit medication in Ghana.
Filling Gaps in the Literature
Professional Applications
This study provides the information and data needed to understand the
geographical spread of the counterfeit problem in Ghana, which is relevant for
intervention. Adequate mechanisms for treating malaria ailments must be in place to have
proper interventions to prevent and fight this disease. Since this study was performed at
different geographical regions in Ghana, it gave us the opportunity to look at the trend of
counterfeit medication within different regions of the country. It can also help us to
measure the impact of an intervention.
Social Change Implications
The implications for positive social change include a better understanding of how
much the anti-malaria medication is counterfeit and the extent of counterfeit medication
in Ghana, which is needed for interventions that will potentially help minimize the
adverse effects of counterfeit antimalarial medication in Ghana.
Framework
For this study, I combined explanatory theory, which is a public health theory,
with the dose response-receptor occupancy theory in pharmacology. Glanz and National
Cancer Institute (2005) write that explanatory theory illustrates the nature of the problem
such as the factors that cause the problem and the changes required to rectify the issues
against malaria. In this case, the research investigated the malaria epidemic and its
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treatment and other related factors affecting the treatment. One of the factors affecting
malaria treatment is the distribution of counterfeit drugs, which works with the dose
response-receptor occupancy theory used in pharmacology, as it was even used to explain
the effect of the amount of dose in a malaria drug, the efficacy of the drug, or toxicity of
the drug (Rang, 2006). Researchers use this theory to examine how the effect or response
to a drug is directly proportional to the number of receptors occupied by that drug. A
drug will only produce a maximum effect if all the receptors needed to elicit the effect or
responses are occupied (Brunton et al., 2011). This means that for antimalarial
medications, the total efficacy can only be achieved if all the receptors needed to destroy
the plasmodium parasite are occupied. A counterfeit drug is defined by WHO (2013) as a
drug whose identity and source has been deliberately mislabeled. Counterfeit products
have a wide spectrum; this includes those with wrong active ingredients, expired drugs,
and those with subtherapeutic amounts of the active ingredient. For a counterfeit drug,
whether substandard or fake, either the receptors are not fully occupied, or they are not
occupied at all. This means that substandard and fake drugs will not produce the required
effect, thereby affecting the treatment and the malaria epidemic.
The burden of malaria is still high in Ghana, with almost 350 cases reported per
1,000 of cases of malaria among young children below the age of 5 years (Asante et al.,
2011). The prompt treatment or management of malaria is necessary for the control and
elimination of the disease (Band et al., 2013). Effective treatment can also reduce drug
resistance since it reduces the frequency of mutation of the parasite. Ineffective treatment
can make matters even worse as it increases the population of resistive strains, which
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makes the disease difficult to treat as it renders current medications ineffective (Tordrup,
Virenfeldt, Andersen, & Petersen, 2011). The WHO highly recommends artemisininbased combination therapies (ACTs); two of the most commonly used are generic ATMT
and LMFT (Lozano et al., 2012). Unfortunately, according to the CDC (2013), it is
estimated that 10% to 30% of all medicines sold in the developing world are counterfeit.
A report from the Institute of Medicine (2013) says that counterfeit drugs were sold in
more than 124 countries in 2011 alone. Most of these counterfeit medications are in subSaharan Africa ranging from about 12% to 50%. Some studies in parts of Africa has
shown that about 45% of sulphadoxine-pyrimethamine (SP) and 33.0% of LMFT were
counterfeit (Amin, Snow, & Kokwaro, 2005). Most of these counterfeit drugs are
shipped from Asia (Newton et al., 2011) and are a result of the lack of effective health
care and regulations. Few studies have been conducted on the quality of the medication
in Ghana, and researchers have worked with limited samples and insufficient theories.
The results of a small pilot study in 2013 on the quality of artemether and lumefantrine
found that 17% of the drugs they tested had quality issues (Affum et al., 2013). Bate et
al. (2008) found that about 35% of the drugs were counterfeit in Ghana and other African
countries; however, they did not look at the efficacy of the drugs (Bate et al., 2008).
Others saw the percentage of counterfeit drugs in Ghana ranging from 54% to 94%
depending on the method used to check the quality of the drug. Using a receptor theory is
more effective in examining counterfeit malaria drugs, because researchers can see the
actual concentration of the drug, which affects efficacy.
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Research Questions
While it may not be possible at this time to ensure all drugs in Ghana are not
counterfeit, it is a goal to strive for. For now, researchers can investigate if a minimum
percentage of the drug in the country is counterfeit and as a result assess a low threshold
for counterfeit product.
RQ1: Is there a difference between the percentage of counterfeit medication in
pharmacies found in the cities and those found in the rural areas?
Ho1: There is no difference between the percentages of counterfeit medication in
pharmacies found in the cities versus those found in the rural areas.
Ha1: There is a difference between the percentages of counterfeit medication in
pharmacies found in the cities versus those found in the rural areas.
RQ2: Is there a difference in the percentage of counterfeit drugs between
pharmacies and licensed chemical sellers?
Ho2: There is no difference in the percentage of counterfeit drugs between
pharmacies and licensed chemical sellers.
Ha2: There is a difference in the percentage of counterfeit drugs between
pharmacies and licensed chemical sellers.
RQ3: Is there a difference in the percentage of counterfeit drugs between
imported artemether and lumefantrine and locally manufactured ones?
Ho3: There is no difference in the percentage of counterfeit drugs between
imported Artemether and Lumefantrine versus locally manufactured ones.
Ha3: There is a difference in the percentage of counterfeit drugs between
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artemether and lumefantrine that is imported versus locally manufactured ones.
RQ4: Is there a difference in the percentage of counterfeit drugs between government
hospitals and those from nongovernmental hospitals?
Ho4: There is no difference in the percentage of counterfeit between government
hospitals and those from nongovernment sources.
Ha4: There is a difference in the percentage of counterfeit drugs between
government hospitals and those from nongovernment sources.
Nature of the Study
This study was a cross sectional correlational study and the samples was chosen
using a statistically suggested sample size to ensure that there is enough power for the
population to reduce any biases. The quantitative method was used because it is the best
way to assess a situation or a problem analytically (Fowler, 2009). This study required
systematic measurement of study samples in the lab using validated analytical techniques.
The study variables were the concentration of artemether and lumefantrine (dependent)
which is measured in milligram per milliliter of solution. The independent variables were
the pharmacies and licensed chemical sellers (LCS) where the samples were acquired,
which included different locations for private and government owned pharmacies,
wholesale stores, and licensed chemical sellers. I acquired the samples from the retailers
and sent them to the lab to determine the concentration of artemether and lumefantrine
using High Pressure Liquid Chromatography (HPLC). The covariate of the study was the
cost of the drugs. A more detailed description of the variables is located in Chapter 3.
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Definition of Terms
Antimalarial medication: Drugs used to prevent or cure malaria. This includes
the treatment individuals with both confirmed and suspected infection. These drugs may
sometimes be used for prevention.
Concentration of drug: The amount of drug per volume of solution. This can
either be milligrams per milliliters or grams of drug per liter of water.
Quality of drug/medication: In this project, the term quality is based strictly on the
amount of drug as compared to the expected amount as written on the label. This was
measured in percentage of the drug that is fake or counterfeit.
Counterfeit/fake drug: For this study counterfeit drugs shall refer to drugs without
the active ingredients and subtherapeutic amounts of active ingredient.
Subtherapeutic drug: Has the correct ingredient, but the amount of drug is less
than the labeled amount.
Active ingredients: The substance/s in the drug that are supposed to provide the
therapeutic effect. In this study, the active ingredients are artemether and lumefantrine.
Dose: The quantity of drugs taken or prescribed.
Drug efficacy: A drug’s capacity to produce a desired effect or endpoint. For an
antimalarial drug, the efficacy is its capacity to kill malaria parasites.
High Pressure Liquid Chromatography (HPLC): An analytical technique used
mostly in chemistry used to separate mixture of substances in liquid at high pressures.
This is used to identify each substance in the mixture for quantification.
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Pharmacies: Stores with registered pharmacists preparing, dispensing, and selling
drugs.
Licensed chemical sellers (LCS): Stores mostly run by pharmacy technicians
approved by the government of Ghana selling and dispensing some drugs without the
supervision of a pharmacist.
Private Pharmacies: Pharmacies run and owned by the private sector and not
government.
Government pharmacies: Pharmacies run and owned by the government.
Wholesale: Outlets distributing drugs to the retail outlets including pharmacies
and LCS.
Cities: Urban communities that have utilities, public transportation, modern
sanitation, large population density, and businesses.
Small towns and villages: Communities lacking some or all utilities like pipe-born
water, public transportation, modern sanitation, and businesses.
Assumptions
This quantitative study investigated the extent of counterfeit drug using the two
most prescribed antimalarial medication (artemether and lumefantrine) in Ghana. This
research included the following assumptions in the study:
1.

The data collected from each pharmacy or LCS in a population represents
the information for the whole population. This assumption was necessary
for the data collected to represent the population.
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2.

That ATMT and LMFT purchased from a store represent the quality of
all ATMT and LMFT from that store. This assumption allowed the use a
few drugs to represent all the drugs in a particular store

3.

Data from ATMT and LMFT was a good representation most popular
anti-malarial medication in Ghana.

4.

The drugs are only acquired via the above mentioned outlets. This means
that the number of all other possible outlets is so small that their
contribution to this data with be insignificant. This validated the fact that
the samples used for this study represented all the drugs in the
population.
Scope and Delimitations

Artemether-lumefantrine combination tablets from public and private (local retail
pharmacies) in Ghana can be obtained in two formalized ways: traditional pharmacies
with a trained pharmacist and LCS. LCS sell drugs mostly in suburbs, small towns, and
villages, without any supervision of a pharmacist, but they are licensed by the
government to sell over-the-counter medication and common medications authorized by
the government. Because these are not well controlled or monitored, the LCS sells
almost the same medications sold by the pharmacies.
Geographically, Ghana is divided into ten regions; the capital of Ghana is Accra
and the second largest city is Kumasi. Most of the pharmacies are in the major cities
within the ten regions. The Greater Accra Region has two main sub cities within it: the
city of Accra and the industrial city of Tema. Kumasi and its surrounding suburbs are the
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main city for the Ashanti Region. According to the Ghana Pharmacy Council, there are
429 Pharmacies and 9,210 licensed chemical sellers throughout the country. Most of the
pharmacies are in the four major cities. The city of Accra has about half (233), Kumasi
has (79) pharmacies, and the other two major cities have 40, and the rest are spread
throughout the country mostly in the bigger towns. The LCS are more spread out as they
serve more remote and rural communities. I assessed these areas, with inclusion criteria
involving all registered pharmacies (private and government) and all licensed chemical
shops in the selected towns; exclusion criteria included unregistered stores that sells
drugs or any person selling drugs on the streets illegally.
A generalization for this study was the assumption that a few drugs from one store
represent the quality (counterfeit or not) of all drugs in that store. Another generalization
was assuming a few randomly picked stores represent the entire pharmaceutical retail
outlets in the country.
Limitations
The choice to study Ghana presents a bias because of my connection to that
country (place of birth), which may have excluded other sub-Saharan African countries
that would present different data. Another limitation of this study was that the study may
not capture all possible outlets, which includes possible illegal outlets that may exist in
the system. If these numbers are significant, this will affect the internal validity of the
study since the outcome of the study may not be a true representation on the population.
Other confounding variables like price of the drug and lack prescription that is acceptable
in Ghana may also have affected the validity of the study. Some of these were solved by
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making sure the data collection process is done correctly, based on statistics and sampling
is random.
Significance of the Study
Malaria is still endemic in sub-Saharan countries like Ghana. It is treatable and
there are several medications in the market; however, some studies have shown that many
of these drugs are counterfeit, with a small pilot study revealing that 30% to 40% of
antimalarial medication counterfeit. If this is true, then any eradication program will
have to include reducing or eliminating counterfeit medication in these countries. Since
there is no data quantifying the percentage of antimalarial drugs that are counterfeit this
study was to solve that problem. This study will give information needed to decide if the
reduction or eradication of counterfeit medication in Ghana and other sub-Saharan
countries should be part of malaria eradications strategies. Since this study was
performed at different geographical regions in Ghana, it will also provide the opportunity
to look at the trend of counterfeit medication within different regions of the country,
which will increase efficiency in intervention and measuring of the impact of such
intervention.
Summary
Over 200 million people worldwide are infected with malaria and more than half
a million people are dying from it per year. Malaria is a treatable disease with several
medications in the market, but several pilot studies have revealed the possibility of
counterfeit antimalarial medication as one of the factors affecting the treatment of
malaria. However, there has not been a comprehensive study looking empirically at the
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extent of counterfeit antimalarial medication in the system (Asuamah, Owusu-Prempeh,
& Antwi-Boateng, 2013). Using Ghana as an example and two of the most common
antimalarial drugs in Ghana—ATMT and LMFT—this study explored the extent of
antimalarial counterfeiting, if any, from pharmaceutical retail outlets in Ghana. This
study aimed to address the lack of data on the extent of counterfeit antimalarial drugs in
Ghana and sub-Saharan Africa in general. Chapter 2 will include an overall review of the
limited literature on the extent of counterfeit antimalarial medication.
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Chapter 2: Literature Review
Introduction
Even though there have been speculations about the extent of the counterfeit
problem in some of the countries that suffer from malaria epidemics, there has not been
an extensive study on the whole country (Ghana) that has empirically determined the
extent of counterfeit antimalarial medication in the system (Asuamah, Owusu-Prempeh,
& Antwi-Boateng, 2013), and there is little to no empirical evidence of the percentage of
drugs in the sub-Saharan region that are counterfeit. Due to this gap in the literature on
counterfeit medication, I empirically determined the percent of antimalarial medication
that is counterfeit in pharmaceutical retail outlets in Ghana.
In this chapter, I will discuss the strategies used to conduct the literature review as
well as the epidemiology, which will include the incidence and prevalence and the mode
of infection of malaria. There will also so be emphasis on past research about malaria,
the problems with counterfeit drugs, and how counterfeit medication affects the malaria.
This chapter will also provide analysis on how drugs are distributed in Ghana, the
sources, and where they are manufactured. In addition, I will discuss the explanatory
theory which is a public health theory combined with the receptor occupancy theory in
pharmacology and how these two theories were applied to the characterization of the
quality of antimalarial drugs in Ghana by looking at the percentage of the drugs that are
counterfeit.
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Literature Search Strategy
Several types and sources of information or data revealing research studies were
used for this literature review. The research included a review of other peer reviewed
manuscripts and studies on malaria and counterfeit drugs. Most of the research was from
primary articles, which means I excluded review articles and reports or studies without
original research. Literature search was done using keywords like malaria, counterfeit
drugs, counterfeit medication, and antimalarial medication, malaria treatment, malaria
in Ghana, and receptor occupancy and explanatory theory in different combinations.
Most of the search criteria was based on literature published from 2008–2014. The
following databases were used: PUBMED, Library of Congress, EMBASE, MEDLINE,
ScienceDirect, Pre-CINAHL, CINAHL, ProQuest and Dissertations & Theses, Web of
Science, and the Walden University database of dissertations. Other search engines
included Google Scholar, and I examined the WHO and the Centers for Disease Control
and Prevention (CDC) websites for relevant information.
Using malaria as a keyword alone gave me 69,103 articles. This was obviously
difficult to use and unfocused, so I combined some of the keywords for better results.
For instance, search results of malaria and Ghana and drugs showed 149 citations; out of
these articles, eight articles were found to be acceptable. Explanatory theory came up
with 27 citations searched as a title, and six citations were acceptable. Ghana and fake
medicine provided five citations, and four were used. The total number of articles used
for this literature review was 117.
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Theoretical Framework
For this study, I combined two theoretical concepts from two disciplines:
explanatory theory, which is a public health theory, with the receptor occupancy theory in
pharmacology.
Explanatory Theory
There is a great amount of evidence that suggested public health intervention and
promotions based on theories are more effective than those without theories (Glanz &
National Cancer Institute [NCI], 2005). Explanatory theory, also known as the theory of
the problem, was first used by Shapiro in psychiatry. The theory is used to illustrate the
nature of a problem by examining the factors that cause the problem that can be changed
(Shapiro, 1953). Researchers have used it in several ways to empirically determine or
test several public health issues (Song et al., 2010), such as testing for postpartum fatigue
in Korea, explaining metabolic depression in hibernation and major depression (Tsiouris,
2005), and it was recently used to build another social epidemiology theory for
depression in mothers (Eastwood, Jalaludin, & Kemp, 2014). It has also been used in
other disciplines such as economics with asset evaluation and human capital and in
education for studies in learning curves and team learning (Vlismas & Venieris, 2009;
Westwood, 1997). The theory helps define the elements that influence particular
behaviors, trends, or situations before moving on to find cause and solutions to the
problem. There are several concepts considered in this theory in relation to an ecological
perspective; this includes intrapersonal, interpersonal, institutional, community factors
and public policy (McLeroy, Bibeau, Steckler, & Glanz, 1988; Stokols, 1996).
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Intrapersonal factors look at individual characteristics that affect behavior; examples are
beliefs, attitudes and personality traits. Interpersonal looks at interpersonal processes and
groups that provide support like families and friends. Institutional factors mostly involve
rules and regulations and informal structures that could help or make a problem worse
(McLeroy et al., 1988). One of the goals of this study was to provide an improved
approach in order to enhance the empirical understanding of the problem before
developing intervention programs for counterfeit antimalarial medication and the malaria
epidemic in general. In this case, the problem is the malaria epidemic and its treatment,
and among the many factors affecting the treatment is counterfeit antimalarial medication
and its distribution. In addition, receptor occupancy theory, which relates more to drugs
and pharmacology, will address the amount of active drugs required for malaria
intervention.
Receptor Occupancy Theory
Receptor occupancy theory is used in pharmacology to explain the effect of the
dose of a drug and the efficacy or toxicity of the drug (Rang, 2006). The receptor
occupancy theory was first postulated by Langley in 1901 after his work on nicotine and
curare, even though this idea of receptors controlling the effect of a drug was furthered by
Ehrlich around the same period. Langley’s model explains how a drugs activity affects
receptors and then quantifies the drug concentration and effect elucidated by the drug,
which links drug action to the number of receptors occupied by that drug (Christopoulos
& El-Fakahany, 1999). Drug effects on biological systems are quantified by assigning
mathematical rules to biological systems (Kenakin, 2008). This is done independent of
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the biological system, since it is essential for the study of drugs mostly done in test
systems. This current study helps to isolate the effect of the drug in different systems and
under different conditions. A very important part of the theory is the assertion that the
amount of drug bound to the cell is directly proportional to the response. Figure 1
describes the proportionality equation between the amount of drug bound to the receptors
and the response.

Figure 1. Relation between drug bound and physiological effect.
E is some physiological effect that happens as a result of the drug. An example is killing
of plasmodium parasite. Emax is the maximum amount of this effect, DR is the amount of
drug bound to the receptor and RT is the total amount of receptors. Retrieved from
http://www.uky.edu/~mtp/pha522drug/OBI836mp06.html

Figure 1 shows that the maximum effect is only realized if all the receptors are
occupied by the drug. Addressing the relationship between effect and receptor
occupancy is shown in Figure 2. In Figure 2, no matter what the relationship, the
maximum effect only happens when all receptors are occupied.
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Figure 2. Relationship between effect and percent receptor occupancy. Source: Brunton
et al, 2011.
Receptor occupancy theory provides the basic framework of drug interactions and
the way the drug behaves on the body, which is known as pharmacodynamics. The
theory states that the effect/response of a drug is directly proportional to the number of
receptors occupied by that drug. It also states that this drug will only produce a
maximum effect if all the receptors needed to elicit the effect or responses are occupied.
The approach could be applied to antimalarial medication, because for antimalarial
medications, the total efficacy can only be achieved if all the receptors needed to destroy
the plasmodium parasite are occupied. Counterfeit drugs have a wide spectrum, which
includes those with wrong active ingredients, those that have expired and relabeled, and
those with subtherapeutic amounts of the active ingredient. For a counterfeit drug,
whether substandard or fake, either the receptors are not fully occupied, or they are not
occupied at all. This means that substandard drugs will not produce the required effect
since they will not occupy all the receptors, or the fake drug will not occupy the receptors
at all, thereby negatively affecting the treatment and the malaria epidemic.
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Combination of Explanatory and the Receptor Occupancy Theory
A combination of the two theories starts with the explanatory theory to ask
questions and examine the problem (Figure 3). The problem is the distribution of
counterfeit antimalarial medication. This theory will ask what the problem is, accessing
the extent of the problem. The next step of the process is the evaluation stage, which
identifies when the receptor occupancy theory comes to play. The evaluation stage will
also look at the concentration on the drugs since this is related to the amount of drug
needed to occupy the receptor.

Figure 3. Theoretical framework.
Transmission and Life Cycle of the Parasite
The plasmodium sp. is the parasite that causes malaria (Zhou et al., 2014). The
parasite uses two hosts—the mosquito (intermediate host) and the human (primary
host)—in its life cycle as shown in Figure 4 (CDC, 2012). There are three sub cycles: the
exo-erythrocytic cycle (liver) and the erythrocytic (blood) cycle in the human host and
the sporogonic cycle in the Anopheles mosquito (Florens et al., 2002). An infected
female Anopheles mosquito transmits the parasite (sporozoites) to the human host during
feeding through the saliva, which it uses to prevent the coagulation of the blood; this is
the exo-erythrocytic cycle (Beck, Logie, & McGregor, 1970). The sporozoites then move
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into the human liver cells where they become schizonts (Mahajan et al., 2008). This
stage can be dormant for even years in some species until they rupture to release
merozoites (Riley et al., 2000). Merozoites then infect red blood cells, initiating the
erythrocytic cycle (Vaughan, Aly, & Kappe, 2008). Merozoites mature into a ring stage
called trophozoites which are responsible for the clinical manifestations of the disease
and also produces the gametocytes which can be ingested by the Anopheles mosquito
after which they enter into the sporogonic cycle (Aguilar et al., 2014). The zygotes are
formed in the stomach of the mosquito, which becomes ookinetes; these are mobile and
elongated which allows them to invade the wall of the mosquito’s stomach where they
develop into oocysts. These then rupture to release sporozoites, which move into the
salivary glands of the mosquito. Sporozoites can then be transmitted into the human host
(Arakawa et al., 2005). As we shall see later, the medication used for the treatment of
malaria disrupts the different parts of the life cycle of the plasmodium parasite.
It is important to know that there are several species of the plasmodium parasite
(P. falciparum, P. vivax, P. malariae, and P. ovale), which adds to the variability of the
signs, symptoms, and treatment of malaria (Kiwuwa et al., 2013). Breeding of Anopheles
mosquitos takes place in water, mostly in stagnant water (Tchouassi et al., 2012). The
longer the life spans of the mosquito, the more severe the epidemic, which is present
mostly in the tropics (Kiwuwa et al., 2013).
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Figure 4. Life Cycle of the plasmodium parasite. Adapted from CDC (2012).
Signs and Symptoms
Malaria symptoms are flu-like on the onset; it is a disease that manifests with
acute fevers, headaches, malaise, and chills (Sarkar, Shah, & Murhekar, 2012).
Generally the symptoms of malaria appear within 1 week to 2 weeks after infection from
the anopheles mosquito (Ohnishi et al., 2007). According to the American Public Health
Association (APHA), his disease could also take up to 1 year to appear, especially with P.
vivax and P. ovale infections. These febrile symptoms are cyclical, and cycle is
dependent on the kind of parasite. An infection by P. vivax or P. ovale has a 48 hour
cycle, P. malariae has 72 hours, but P. falciparum does not cause any cyclic fever which
happens to be one of the major signs of malaria infection (APHA, 2008). Progression to
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severe illness can result within 24 hours of no treatment, and this can be fatal (Anstey,
Douglas, Poespoprodjo, & Price, 2012). Adults in malaria endemic areas can develop
partial immunity (Snow & Marsh, 1998), which is why children and older populations
develop severe malaria frequently after infection (Griffin, Ferguson, & Ghani, 2014;
Pistone, Diallo, Mechain, Receveur, & Malvy, 2014; Rizvi et al., 2013). Some of the
severe symptoms include anemia, which can be fatal; metabolic acidosis, which results in
respiratory distress; and cerebral malaria. Several organs can be affected, which results
in the fatalities during malaria infection (Lomar et al., 2005).
Diagnosis
Prompt diagnosis is necessary for effective management, treatment, and control of
the transmission of malaria (Tangpukdee, Duangdee, Wilairatana, & Krudsood, 2009).
Lack of and delay in the diagnosis of malaria affects the treatment, which happens to be
one of the leading causes of complications and death from malaria infection (WHO,
2012). The diagnosis involves the identification of the parasites at the part of the life
cycle they are in and antigens in the blood of the patient. Diagnosis can be difficult,
especially in endemic areas, since there are five different species of the parasite and each
have a unique product, endemicity, and organism within the life cycle. Other differences
include different levels of transmission, signs and symptoms, immunity, and parasitemia
(Iborra, Garcia, Carrilero, & Segovia, 2013). The diagnosis can also be difficult in areas
like the US or other western nations where the disease is not endemic and health care
personal have little to no experience with the disease (Magill, 2006). The diagnosis of
malaria can be broken down into clinical, laboratory, and molecular diagnosis (Harvey et
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al., Polage et al., 2006, 2013; Reynolds et al., 2013; Stephens, Phanart, Rooney, &
Barnish, 1999), but clinical diagnosis is the most widely used and the most inexpensive
form of diagnosis. This is based on the symptoms and signs of the disease (Maltha &
Jacobs, 2011), but because the symptoms at the early stage include fever, headache,
weakness, muscle and abdominal pain, malaise, and vomiting, it is hard to identify a
specific disease among the many other febrile diseases like bacterial and viral infections
that also include these symptoms. There are several algorithms for diagnosis based on
these symptoms, but these have been shown to be nonspecific (<10%) even though they
are about 100% sensitive especially in Africa (Perkins et al., 1997). This could also
result in over diagnosis of malaria and studies have shown that some of these algorithms
leads to >30% over diagnosis (Bhandari, Raghuveer, Rajeev, & Bhandari, 2008; Tarimo,
Minjas, & Bygbjerg, 2001).
Due to the issue of over diagnosis that occurs in clinical diagnosis, other forms of
diagnosis like laboratory diagnosis are used, which will complement or confirm the
clinical diagnosis. Laboratory diagnosis is based on conventional microscopy and
technicians will look for the parasites in blood smear which is sensitive and specific but
requires equipment, good training and time, serological test, which are based on
antibodies against parts of the reproductive cycle of the parasite and several rapid
diagnostic tests in the market (Fancony, Sebastiao, Pires, Gamboa, & Nery, 2013;
Gomes, Espino, Abaquin, Realon, & Salazar, 1994; Maina et al., 2010; Masanja et al
2010). Molecular diagnosis of malaria is based on modern molecular biological
techniques like polymerase chain reaction (PCR) which is the gold standard for the
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diagnosis of malaria. It has both high sensitivity and specificity (Demiraslan et al., 2013;
Khan et al., 2013; Morassin, Fabre, Berry, & Magnaval, 2002). It also requires well
trained personnel to test. Moreover, WHO (2012) recommends that suspected malaria
should be confirmed using laboratory/molecular techniques or rapid diagnostic test before
initiating treatment.
Prevention
The way to prevent malaria infection is to control the life cycle of the plasmodium
parasite. Since the life cycle is affected by the anopheles mosquito vector, the control of
the anopheles mosquito is the main way to reduce the transmission of malaria within a
population. The most popular forms of vector control are through the use of insecticidetreated mosquito nets (ITNs), indoor spraying with residual insecticides and antimalarial
medicines. Chemoprophylaxis can also be used especially for travelers and for personnel
in the military drugs such as mefloquine, doxycycline or atovaquone-proguanil are used
to suppress the malaria infections (Grobusch, 2014; Kersgard & Hickey, 2013). Pregnant
women living in areas endemic to malaria are recommended by WHO to use preventive
treatment with sulfadoxine-pyrimethamine intermittently after the first trimester during
their prenatal visits. The same applies to infants living in endemic areas, preventive
treatment with sulfadoxine-pyrimethamine is recommended with routine vaccinations
(WHO, 2012). Another important mechanism of controlling mosquitos is the use of
insecticides. An example was the use of dichlorodiphenyltrichloroethane (DDT) which
was used to eradicate malaria in the US and parts of Europe but was ban by the WHO due
to alleged adverse effects on the environment (Wang et al., 2013). The spraying of other
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insecticides both indoor and outdoor used to kill the adult mosquitos has been shown to
be effective especially if it is combined with other preventative measures like mosquito
nets and chemoprophylaxis (Kigozi et al., 2012). Mosquitos are growing resistance to
some of the common insecticides like the pyrethroids, which are the class of insecticides
mostly used for ITNs (Gatton et al., 2013; Hewitt, Delacollette, & Poirot, 2013).
Treatment/Management
It is important to note that malaria is fully preventable and treatable, and treatment
or management of malaria is necessary for the control and elimination of the disease. The
prompt treatment of malaria is part of the secondary prevention, which reduces the
transmission and spread of the disease (Band et al., 2013). Effective treatment can also
reduce drug resistance since it reduces the frequency of mutation of the parasite. As
mentioned before, lack of treatment can cause very serious complications. Additionally,
ineffective treatment can make matters even worse as it increases the population of
resistive strains, which makes the disease difficult to treat as it renders current
medications ineffective (Tordrup, Virenfeldt, Andersen, & Petersen, 2011). One such
drug is chloroquine which was very effective as mono-therapeutic drug for both
complicated and uncomplicated malaria (Tonnesmann, Kandolf, & Lewalter, 2013). Until
recently, chloroquine was the prototypic drug due to its effectiveness; it is very cheap,
has the best safety profile compared to other antimalarial drugs and one of the most
studied (Pfeiffer et al., 2008). Unfortunately, it is not effective in many endemic areas
and may not be recommended for treatment in most of these areas even though it is still
the first line in some sub-Saharan countries (Takahashi et al., 2012). The focus of
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malaria treatment and management addresses the treatment of the disease, monitoring of
parasitic drug resistance, chemoprophylaxis and reduction of the spread of the parasite.
There are several antimalarial medications, and most of these have been in existence for
many years. The WHO (2012) advises against the use of any form of mono-therapy for
the treatment of malaria. It recommends combination of at least two active ingredients
with different mechanisms of actions. This could be one drug with these ingredients or
combinations of drugs. The WHO highly recommends artemisinin-based combination
therapies (ACTs). There are five ACTs currently recommend by WHO, and the choices
of which combination is normally based on therapeutic efficacy studies (WHO, 2012).
Antimalarial Medications
Most of the antimalarial drugs are active against different parts of the life cycle of
the parasite. The most common medications include quinine and it agents, chloroquine,
amodiaquine, pyrimethamine, proguanil, sulfonamides, mefloquine, atovaquone,
primaquine, artemisinin and its derivatives, halofantrine, doxycycline and clindamycin.
The most common non-artemisinin based combination therapies are sulfadoxinepyrimethamine, pyrimethamine and chloroquine, pyrimethamine and lumefantrine,
pyrimethamine and mefloquine. The most common artemisinin-based combination
therapies (ACTs) are artemether and lumefantrine, artesunate and amodiaquine,
artemether and mefloquine, artemether and sulfadoxine/pyrimethamine,
artesinin/piperaguine/primaquine and dihydroartemisinin-piperaquine (Deye et al., 2012;
Fryauff et al., 2007; Leggat, 2012; Newton et al., 2011; Njau et al., 2013; Osei-Akoto,
Orton, & Owusu-Ofori, 2005; Phanouvong, Dijiba, et al., 2013; Phanouvong, Raymond,
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et al., 2013; Tsiamis, Piperaki, & Tsakris, 2013; Wasnik, Manohar, Humaney, & Salkar,
2012).
Antimalarial Drug Policy in Ghana
According to the Ministry of Health of Ghana (2009), there have been several
initiatives to roll back malaria for many years mostly with the help of the WHO.
Unfortunately, malaria is still endemic in Ghana, and it is still the number one cause of
death and mortality in Ghana. Like other countries, the control of malaria in Ghana also
suffers from the development of drug resistance by the plasmodium parasites especially
from monotherapy. Because of this, Ghana went in line with WHO’s antimalarial use of
ACT based recommendations for all countries. Based on this, artemether-lumefantrine is
used in Ghana for uncomplicated malaria. Other alternative artemisinin combinations
recommended for uncomplicated malaria are artemether/ lumefantrine and
dihydroartemisinin/piperaquine combinations. Quinine is used for treatment failure and
complicated malaria. Intramuscular artemether can also be used for complicated malaria.
Similar to most countries, monotherapy is not recommended in Ghana (Ministry of
Health, 2009).
General Epidemiology of Malaria
The intensity of malaria transmission depends on factors related to the parasite,
the mosquitos, the human host, and the environment. There are several ways malaria is
transferred to humans. The most common way of malaria transmission especially in areas
endemic to the infections is through the bite of the anopheles mosquito also known as the
Mosquito-Borne Malaria. According to the CDC (2013), malaria is transmitted
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exclusively through the bites of Anopheles mosquitoes. A small subset of these is the
imported malaria, which is a factor in countries that have already eradicated malaria.
These can also cause “Airport" Malaria. This is when mosquitoes are transported by
plane from one country to the other (from an endemic to a non-endemic country). The
other kind of malaria is the Congenital Malaria. In congenital malaria, infected mothers
transmit parasites to their child during pregnancy before or during delivery. This is very
common in immigrants and refugees (CDC, 1981; Tittle et al., 1982).
Transfusion-Transmitted Malaria is generally very rare, but since malaria is a
blood borne disease there is always a potential of it getting transmitted during blood
transfusion, organ transplantation and even shared needles (Ozkurt, Erol, Kadanali,
Altoparlak, & Tasyaran, 2005; Rojo Medina, 2014). There is still no approved way to
screen for malaria parasites in donated tissues; this is partly because most tests are not
that sensitive. Even though this is rare, Transfusion-Transmitted Malaria can be common
in places endemic with malaria because malaria screening is still not performed in many
of these countries even though it is recommended by international policies (Owusu-Ofori,
Parry, & Bates, 2010)
According to the WHO (2013), in 2010 there was an average of about 220 million
cases globally with over 650,000 estimated deaths. Most of these deaths (91%) came
from Africa, and a majority of the deaths globally (86%) came from children under 5
years of age. This shows that malaria is still a big health problem. Majority (91%) of the
malaria cases were due to P. falciparum infection (WHO, 2013). Death caused by malaria
in Africa is very high compared to that of the rest of the world. It is more so in sub-
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Saharan Africa. Even though majority of the prevalence rate of malaria is in Africa, the
disease burden and trends vary widely across the continent. The disease burden in the
southern African countries is much better than the rest of the continent (Cibulskis et al.,
2007; Griffin et al., 2014).
Populations at Risk
As mentioned earlier, malaria is endemic in sub-Saharan Africa, but it is also
prevalent Latin America, Asia, Middle East and some parts of Europe but in relative
terms, it is not as much as the sub-Saharan regions of Africa (Haq, Mahjour, & Khan,
2013; Makdoembaks & Kager, 2000; Vanderelst & Speybroeck, 2013; Yasuoka &
Levins, 2007). According to the WHO (2013), almost 100 countries and territories had
populations with ongoing malaria transmission. Out of all the populations, young
children, older populations, immune-incompetent patients and pregnant women have the
highest risk of complications from the infections.
Malaria Epidemiology in Ghana
Even though there are differences between the regions in Ghana with the northern
part being mostly savanna and middle/southern part being the rain forest, the malaria
endemic is still very high in all regions. The disease burden of malaria is still very high in
Ghana with almost 350 cases reported per 1000 of cases among young children below the
age of 5 (Asante et al., 2011). With all the effort to eradicate or decrease the incidence
and prevalence rate of malaria, there is little to no evidence that there has been a decrease
in the percentage of hospital admission and death from malaria in recent years (WHO,
2011). The transmission rate in Ghana is among the highest in Africa and in the world
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with almost 100% of the population being at risk for infection (WHO, 2011). This is not
different from most of the other West-African countries. The transmission is mostly due
to P. falciparum. It is also worth noting that most of the data collected is based on
hospital admissions and deaths, there are a lot of people who go under the radar
especially through self-medication (WHO, 2011). In one study carried out in the rain
forest area of the country, there were approximately 270 infective mosquito bites per
person per annum. In another study, it was found that prevalence rate of the malaria
infection was > 50% especially among children < 5 years. Children < 5 years of age had
at least 7 episodes of malaria infection per year (Owusu-Agyei et al., 2009).
Counterfeit Drugs
The WHO (2011) cited the Black's law dictionary, when it tried to define
counterfeit drug. A counterfeit drug was defined as an imitation of drug prepared without
the rights or permission from the original manufacturer with the intention of deceiving
and scamming consumers (WHO, 2011). The problem is that there is not a universally
accepted definition and theses definitions vary from country to country. Each country or
organization has its own definition. For instance, the US Food and Drug Administration
(USFDA) define a Counterfeit medicine as a fake medicine, which could contain the
wrong active ingredient or the right ingredient contaminated or right active ingredient,
but the WHO defines a counterfeit as a drug whose identity and source has been
deliberately mislabeled. Counterfeit drugs have a wide spectrum which includes drugs
without the active ingredients, those that have fake active ingredients, expired drugs and
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sub-therapeutic amounts of active ingredient (Attaran et al., 2012). A sub-therapeutic
drug has the correct ingredient, but the amount of drug is less than the labelled amount.
Factors That Fuel Counterfeit Drugs
Generally, this has to do with economics. As mentioned earlier, there are millions
of dollars of profit being made from these drugs. Producing good quality drugs come
with a price. It cost billions of dollars to come out with one drug; therefore, falsifying
drugs has been dubbed a “the perfect crime” because it is very profitable, and it costs
much less to make (Dondorp et al., 2004). Another problem is from tiered productions
where companies make inferior drugs to inferior markets due to lack of enforcement and
less stringent regulations, and it is mostly described as legal. This is basically exploitation
by some companies; they produce lower quality drugs, which fit in the definition of
counterfeit drugs (Caudron et al., 2008). These systems tie into the weak regulatory
systems; countries with high levels of counterfeit drugs have very weak regulatory
authorities (Dondorp et al., 2004). The WHO found that in sub-Saharan African countries
most of these organizations have no legal authority to perform inspections. As a result, it
made it easier for counterfeit medicines to infiltrate the market (Zumoff, 2007). For
instance in 2007,a Chinese regulator through corruption and bribery issued several
fake/forged in one of the provinces (Liu, 2010). Another important factor is the lack of
awareness and Action. Without a clear idea of the extent of the counterfeit problem, it is
difficult to come with the appropriate intervention strategies. The awareness of the
problem is very low in many of those countries even though it is beginning to become an
important factor for policymaking. In places where there is some awareness, there is still
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very little knowledge of the extent of the problem (Cockburn, Newton, Agyarko,
Akunyili, & White, 2005).
Finally, a big problem is the disease burden in these developing countries,
combined with extreme poverty, bad health care systems (Wang et al., 2014). People
have no choice but to go for cheap medication, cut corners, which opens patients up to
counterfeits drugs. Socioeconomic factors play a major role in this (Krefis et al., 2010).
Assessment of the Global Counterfeit Antimalarial Drug Problem
The extent of counterfeit drug globally is not known since there has not been a
study that looks at this problem globally. Nevertheless, it is a problem that affects almost
every country rich or poor; but, it has a worse adverse effect on poorer countries
(Caudron et al., 2008). According to the CDC (2013), it is estimated that 10% to 30% of
all medicines sold in the developing world are counterfeit. This is estimated to be 1% in
the industrialized countries. One question that begs asking is whether the problem with
counterfeit drugs has either been ignored or underestimated because it is becoming
crucial public health problem for malaria and other diseases (Newton et al., 2008).
Financially, even though it creates a burden on these countries, the manufactures have
lots to gain because it is very lucrative with an estimate of >15% of pharmaceutical sales
worldwide with most of it (>60%) in developing countries (Newton et al., 2006)
A report from the Institute of Medicine (2013) says that according to a consortium
of major drug companies, counterfeit drugs were sold in more than 124 countries in 2011
alone. Several studies on counterfeit drugs have been conducted in many countries
mostly in Africa and Asia as these continents have the highest prevalence of counterfeit
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medications. Majority of these studies were on antimalarial medication and
antimicrobials in general (Newton et al., 2011). Majority of these counterfeit medications
are in sub-Saharan Africa ranging from about 12% to 50 %. South eastern Asia follows
very closely with range with about 10 to 40% (Almuzaini, Sammons, & Choonara, 2013).
Amin and Kokwaro (2005) studied the quality of sulphadoxine-pyrimethamine
(SP) and lumefantrine (LMFT) drugs given as over the counter medication (OEM)
communities Kenya. These drugs are OEM because most people self-medicate after
infection. They found that about 45% of SP and 33.0% of LMFT were counterfeit
(Amin, Snow, & Kokwaro, 2005). A cross sectional survey to access pharmacies selling
antimalarial drugs in Southeast Asia (Laos, Myanmar, Vietnam, Thailand and Cambodia)
found that 53% of the tablets did not contain the right antimalarial medications. Four
years later, collaborative investigation into the counterfeit artemether in South East Asia
was carried out involving countries including Vietnam, Laos, Cambodia, Thailand and
Myanmar. Several professionals were involved including chemists, palynologists, police,
healthcare personnel and criminologists with the coordination from International
Criminal Police Organization (INTERPOL). Using High Pressure Liquid
chromatography, the investigators confirmed that almost 50% of artemether drugs were
counterfeit (Newton et al., 2008). This is a huge problem in mainland Asia and the same
issue applies in Africa, as most of these counterfeit drugs are shipped from Asia (Newton
et al., 2011).
Developing countries like Ghana lack well established regulatory organizations;
these countries also tend to have high poverty and are endemic to infectious diseases like
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malaria (Barimah & Mensah, 2013; Kassebaum et al., 2014). Ghana has grappling
challenges in healthcare with millions of people lacking access to health care and most
people relying on local stores, medicine men and women, pharmacies and licensed
chemical sellers for medical advice and treatment. The lack of effective heath care makes
the system very vulnerable and easy for counterfeit medication to infiltrate the market. In
recent years, there has been some coverage about counterfeit antimalarial dugs in Ghana,
and the awareness was raised because it directly affected an influential person. (Daily
Guide, 2013). It is believed that majority of the counterfeit medication comes from South
east Asia (Bate & Hess, 2010). But the extent of counterfeit medication is not known
except for a few publications in a few small towns in Ghana (Asuamah et al., 2013; Bate
& Hess, 2010).
Previous Work on Counterfeit Medication in Ghana
There have been very few studies looking at the quality of the medication in
Ghana. A pilot study conducted in 2013 looked at the quality of artemether and
Lumefantrine tablets in a fishing village in an attempt to look at the quality in fishing
villages in Ghana (Affum et al., 2013). The researchers randomly sampled blister packs
of antimalarial tablets from a small fishing village. They used protocols from the
International Pharmacopoeia and Global Pharma Health Fund Minilab (IPGPM) to assess
the quality of the tablets, and the analytical procedure used was High Pressure Liquid
Chromatography (HPLC). They found that 17% of the drugs they tested had quality
issues (Affum et al., 2013). The advantage of doing this is that it was pilot project, so
they focused on a small little village. However, the caveat is that it hardly tells us
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anything about the counterfeit problem in Ghana as a whole. In the assessment of
counterfeit medication in Ghana, the different outlets have to be taken into
considerations. The main outlets include drugs sold by the government hospitals, the
large pharmacies and the small scale licensed chemical sellers (FHI360, 2013). The
demographics of fishing and non-fishing communities may be different, so it may be
important to have a larger size sample covering different groups and demographics.
There are studies that show that the antimalarial behaviors between different regions are
different. For instance, behavior between urban centers and villages were different, and
this could affect the extent of counterfeit medication (Gardiner, Biggar, Collins, &
Nkrumah, 1984). Another study looked at substandard and falsified anti-tuberculosis
drugs in 19 cities in Africa, Asia and South America. Ghana was one of the countries in
Africa that was tested. This study was not focused on Ghana so the sample size in Ghana
was very small, which does not inform us about the whole country. Once again, it did not
take into consideration the different ways that people acquire their medication in Ghana
(Bate, Jensen, Hess, Mooney, & Milligan, 2013). Bate, Coticelli, Tren, and Attaran
(2008) also studied the quality of antimalarial medication in six countries including
Ghana, Kenya, Nigeria, Rwanda, Tanzania and Uganda. They studied several
antimalarial drugs and found that on the average 35% of the drugs were counterfeit.
Because they were using many countries and several antimalarial drugs, they had very
few samples in each cohort. They sampled only 37 tablets from Ghana, which is quite
small. No statistical reason were given for choosing 37 tablets (Bate et al., 2008).
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Stanton et al. (2012) looked at the quality of uterotonic drugs in Ghana. Ampules
were purchased from three districts with different characteristics in Ghana; these were
coastal, forest and savannah districts. They found that most (86% to 100%) of the
different drugs did not meet the quality standards set by WHO. This study did not take
into consideration the vast difference in the demography within these regions, the
population differences and difference between the various points of sales (Stanton et al.,
2012). Bate and Hess (2010) looked at the quality of antimalarial drug quality in Accra
and Lagos, which are the capital cities of Ghana and Nigeria respectively. In this study,
the percentage of counterfeit drugs in Ghana ranged from 54% to 94% depending on the
method used to check the quality of the drug. The researchers used what they called a
visual method and analytical tests using Raman spectrometer. The problem with this
study is that they focused their sampling at the capital city only and their sampling
method was only from private pharmacies. Only 18 pharmacies were sampled in Ghana
(Bate & Hess, 2010). There are 429 pharmacies and 9210 licensed chemical sellers in the
country (FHI360, 2013), any study being done in Ghana should statistically represent
these outlets. Most of these studies used high pressure liquid chromatography (HPLC) as
the analytical techniques used to measure the concentration of the drug.
Conclusions
Malaria is still endemic in many places especially in the sub-Saharan region of
Africa. There are several medications that can be used for the treatment and prevention
the disease. Unfortunately, there are studies and reports that show that some of these
countries are infiltrated with counterfeit antimalarial medication. Several studies have
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been done to check the quality of drugs especially antimalarial drugs. Ghana is one of the
countries with very high rates of malaria infection. A literature review shows very few
studies attempting to assess the quality of drugs in Ghana. Majority of these studies were
not comprehensive enough. The data were not comprehensive, most were pilot studies,
which focused on very small populations. Sampling seemed arbitrary with no statistical
basis on how the populations were selected. Most of the research studies were all focused
on small regions in the country, which did not tell us much about the quality of drugs in
the whole country. The previous studies showed vast variability of the results, which did
not substantiate a systematic pattern for arriving at a conclusive state. They range from
hardly any counterfeit drugs to almost 90% of the drugs being counterfeit. Most of the
sampling done for these studies was from samples collected from retail outlets. None of
studies considered the different kinds of retail outlets used in Ghana. Therefore, there is a
need for a more comprehensive study that provides a quantitative and systematic
approach and address the extent of counterfeit antimalarial drugs in Ghana.
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Chapter 3: Research Method
Introduction
In this chapter, I will address the research design, rationale of the research, and
the study variables. I will also evaluate the target population, sampling procedure, and
the instrument for analysis in addition to providing operationalization of variables and
assessing the data analysis and threats to validity. Next, I will identify the software for
analyses and evaluate possible ethical concerns. Finally, I will summarize the design and
methodology.
Study Purpose
There are several medications in the market used for malaria treatment. It is
believed that most of these drugs are counterfeit. Unfortunately, the areas suffering most
from malaria seem to have a higher prevalence of counterfeit medication. Any
eradication program will have to include reducing or eliminating counterfeit medication
in the systems. Because there is no data quantifying the percentage of these drugs that are
counterfeit, the purpose of this study was to empirically assess the poor quality of
antimalarial drugs in Ghana. I did this by investigating the most popular or prescribed
antimalarial tablet artemether-lumefantrine, as this tablet is recommended by the Ghana
Ministry of Health (2009) as the first line for uncomplicated malaria.
Research Design and Rationale
This was a cross sectional correlational study that qualifies as quasi-experimental
due to lacking a control group, which is a part of what makes a study experimental. The
rationale of the study was to determine the quality of antimalarial medication and to
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investigate possible sources of the variation in quality in Ghana. The actual amount of
active ingredients of the two most prescribed antimalarial drugs, artemether and
lumefantrine, were compared to the expected or labeled amount. This study required
systematic measurement of study samples in the lab using validated analytical techniques.
As Fowler (2009) describes, the quantitative method is the best way to assess a situation
or problem analytically, which is why it was used in this study. According to Creswell
(2009), one of the hallmarks of quantitative methodology is the analytical part of the
study; for this study, the analytical part was the quantitative measurements used to
determine the relationship among the variables. It is also important to point out that this
study was not intended to prove a causal relationship; rather, it is descriptive. The aim of
the study was to empirically define the problem with the quality of antimalarial drugs in
Ghana, as empirical knowledge of the problem can provide a sustainable way of finding a
solution.
Study Variables
The study variables were the concentration of artemether and lumefantrine, which
is measured in milligram per milliliter of solution. These were the dependent variables as
shown in Table 1. The independent variables are the pharmacies, LCS, and their
locations. This includes those acquired from private and government run pharmacies in
cities, small towns, and wholesale companies (Table 1). It was also important to see if the
cost of the drugs was different and if it had an effect on the other study variables. This
was also considered as a possible covariate (Table 1).
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Table 1
Study Variables
Dependent

Independent

Covariate

Concentration of artemether (mg/ml)
Concentration of lumefantrine (mg/ml)
Private pharmacies
Cities that the private pharmacies are locates
Small towns and villages that the private pharmacies are
located
Government Pharmacies
LCS
Cities that the LCS are located
Small towns and villages are located
mPedigree scratch-off panel
Cost of Drugs

Target Population
I examined artemether-lumefantrine combination tablets, which in Ghana can be
obtained in two formalized ways: traditional pharmacies with a trained pharmacist and
licensed chemical sellers (LCS). LCS sell drugs mostly in suburbs small town and
villages, with no supervision of a pharmacist, but are licensed by the government to sell
over-the-counter medication and common medications authorized by the government.
Because these are not well controlled or monitored, the LCS sells almost the same
medications sold by the pharmacies.
The tablets were obtained from a variety of locations in Ghana. A majority of the
pharmacies are in the major cities within ten regions. According to the Ghana Pharmacy
Council, there are 430 Pharmacies and 9,210 Licensed Chemical Sellers throughout the
country. A majority of the pharmacies are located in four major cities: the city of Accra
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has about half (233), Kumasi has (79) pharmacies, and 40 are in the other 2. The LCS
are more spread out as they serve more remote and rural communities.
Sampling Procedures
Stratified sampling was used to group and sample the population of the town or
city based on the pharmacies per population density. For the sampling of the licensed
chemical sellers, simple random sampling was used. In addition, for the pharmacy stores,
after the stratification method was done, simple random sampling was used. The goal of
the study was to have a power of .08 (80%), with a Cohen specification of a large effect
size of 0.5 for pharmacies and medium effect size of 0.3 for LCS. For each hypothesis, a
95% confidence with the alpha level (type 1 error) set to 0.05 (5%) was assumed. Using
Gpower 3.1 software, the total number of observation in this study was 141. This
represented 32 pharmacies and 109 LCS. The numbers of samples that represented
pharmacies and LCS found in the cities were 16 and 39 respectively. The numbers of
samples that represented pharmacies and LCS found in small towns/villages were both
16, and the number samples for local and imported drugs were 141 each. The total
number of samples representing local and government sources was 141 and 16 (from 10
regional and 6 district capital towns) respectively.
Table 2 below shows the number of pharmacies with their samples for each
stratum and Table 2 and Table 3 show the towns that were randomly picked for sampling
of the pharmacies. Half of the samples were from the cities and the other half from small
towns/villages, as LCS are more spread out as they serve more remote and rural
communities. Half of the LCS sampling was from towns that were already sampled for
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pharmacies (Table 3 and Table 4), and the other half was from towns/villages with no
pharmacies (Table 5). Inclusion criterion for pharmacies was that they were stores run by
registered pharmacists as defined by the Ghana pharmacy board; exclusion criterion for
pharmacies was that they were LCS and stores without registered pharmacists. Inclusion
criterion for LCS was that they were stores without registered pharmacists; exclusion
criterion for LCS was that they were pharmacies and stores with pharmacists. The
government-run pharmacies are located in mostly in the cities and the bigger towns.
Each Region has an average of four government-run hospitals or clinics; sampling was
done from two of the hospital pharmacies in each region. Cities like Accra and Kumasi
with many pharmacies and LCS will have their sampling done by taking samples from
every 10th pharmacy and LCS going from North to South.
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Table 2
Number of Private Pharmacies in Ghana by Town/City
Town/City
Accra
Adenta
Aflao
Agogo
Agona Swedru
Akim Oda
Anloga
Asamankese
Ashiaman
Bawku
Berekum
Bolgatanga
Cape Coast*
Dome
Effiakuma
Ejura
Ho
Kintampo
Koforidua
Konongo
Kumasi
Lashibi
Madina
Mampong
Nkawkaw
Nsawam
Nungua
Obuasi
Oduponkpehe
Prestea
Savelugu
Sekondi-Takoradi
Suhum
Sunyani
Taifa

Number of Pharmacies
233
1
1
1
1
1
1
1
1
1
1
1
10
1
1
1
1
1
8
1
79
1
1
1
1
1
1
4
1
1
1
20
1
8
1
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Tamale
Tarkwa
Techiman
Tema
Teshie
Wa
Wenchi
Winneba
Yendi
Total

5
2
3
24
1
1
1
1
1
429

Table 3
Number of Pharmacies and LCS Sampled by City

City
Accra
Cape Coast
Koforidua
Kumasi
Sekondi-Takoradi
Sunyani
Tamale
Tema

Number of
Pharmacies
7
1
1
3
1
1
1
1

Number of LCS
23
1
1
10
1
1
1
1
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Table 4
Number of Pharmacies and LCS Sampled by Small Town/Village

Small Towns /Villages
Agogo
Agona Swedru
Akim Oda
Anloga
Bawku
Bolgatanga
Effiakuma
Kintampo
Konongo
Mampong
Nkawkaw
Savelugu
Suhum
Wa
Wenchi
Yendi

Number of
Pharmacies
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1

Number of LCS
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
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Table 5
Number of LCS in 10 Regions in Ghana with No Pharmacies
Region
Greater Accra Region

Western Region

Ashanti Region

Northern Region

Upper East Region

Upper West

Volta Region

Brong Ahafo Region

Eastern

Cape Coast

Towns
Ashaiman
Adafoah
Taifa
Dome
Bobiani
Half Assini
Dunkwa
Kumenda
Tepa
Bibiani
Agogo
Pekyi
Bole
Zabzugu
Nyankpala
Bimbilla
Navrongo
Garu
Zebila
Winkogo
Yala
Nabolo
Jirapa
Hamale
Denu
Jasikan
Kpandu
Hoehoe
Tuobodom
Jema
Brumasi
Jema
Asene
Kpong
Kade
Oda
Saltpond
Praso
Brakwa
Komenda

Number of LCS
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
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Research Questions and Hypotheses
It may not be possible at this time to detect all the counterfeit medication in
Ghana, and we may not be able to detect it for ATMT and LMFT either. However, we
can find out the minimum percentage of artemether and lumefantrine in Ghana that is
counterfeit, and which are good predictors of the quality antimalarial medication. Four
research questions and hypothesis were used to investigate this:
RQ1: Is there a difference between the percentage of counterfeit medication in
pharmacies found in the cities and those found in the rural areas?
Ho1: There is no significant difference between the percentages of counterfeit
medication in pharmacies found in the cities versus those found in the rural areas.
Ha1: There is a significant difference between the percentages of counterfeit
medication in pharmacies found in the cities versus those found in the rural areas.
RQ2: Is there a difference in the percentage of counterfeit drugs between
pharmacies and licensed chemical sellers?
Ho2: There is no significant difference in the percentage of counterfeit drugs
between pharmacies and licensed chemical sellers.
Ha2: There is a significant difference in the percentage of counterfeit drugs
between pharmacies and licensed chemical sellers.
RQ3: Is there a significant difference in the percentage of counterfeit drugs
between those drugs imported and drugs locally manufactured?
Ho3: There is no significant difference in the percentage of counterfeit drugs
between those drugs imported versus drugs locally manufactured.
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Ha3: There is a difference in the percentage of counterfeit drugs between those
drugs imported versus drugs locally manufactured.
RQ4: Is there a correlation between the mPedigree scratch-off panel on the
packaging and percent of counterfeit drugs?
Ho4: There is no significant difference between the mPedigree scratch-off panel
on the packaging and percent of counterfeit drugs.
Ha4: There is a significant difference between the mPedigree scratch-off panel on
the packaging and percent of counterfeit drugs.
Instrumentation and Operationalization of Constructs
Operationalization
In order test the hypotheses, the variables had to be identified and defined. The
operational definitions of the variables are in Table 6.
Table 6
Variable Type

Variable
Concentration of
artemether (mg/ml)

Dependent
Concentration of
lumefantrine (mg/ml)

Independent

Private pharmacies

Continued on next page

Operational Definition
The concentration of the artemether and lumefantrine
represents the amount of drug per unit volume of water. This
will allow us to compare the various amounts on the drugs on
the same scale and units.

Private pharmacies (stores run by at least one registered
pharmacist) in cities.
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Variable Type

Variable

Operational Definition

Independent

Cities

Cities are defined as urban communities that have utilities,
public transportation, modern sanitation, large population
density, and businesses.

Small towns and
villages

Small towns and villages lack some or all utilities like pipe
born water, public transportation, modern sanitation and
businesses.

Licensed chemical
sellers (LCS)

Licensed chemical sellers (stores not run by registered
pharmacists) in cities

mPedigree scratch-off
panel

The mPedigree scratch-off panel, is intended to protect against
counterfeit medication by labeling medication using unique
codes, which are verified by SMS. The code is sent via SMS to
a global hotline for verification. A response is sent back within
seconds to confirm or deny the authenticity of the drug

Cost of Drugs

The cost of the medication may affect the quality of the drug.
The cost of every table will also be recorded and tracked to see
if it is a possible covariate.

Covariate

Data Collection
In order to test samples, data was collected from the various kinds of retail stores
described in the hypotheses and transferred into an excel sheet.
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Determination of the concentration of artemether and lumefantrine
The concentration of artemether and lumefantrine was determined using High
Performance Liquid Chromatography (HPLC). This was performed at the Mayo Clinic
Pharmacology Shared Resource Center in Rochester, MN. This lab is a certified lab that
pharmacologic expertise, methodologies, and services especially for phase I and II trials
funded by the National Cancer Institute (NCI). This removed the complication of dealing
with customs and shipping these drugs to the US for measurement. They have several
years of experience developing, approving, and validation methods for testing the
concentration of drugs for clinical trials. HPLC is an analytical method used for
separating mixtures and quantitation the amount of the analytes in the mixture. It is the
method recommended by the US Food and Drug Administration (USFDA) for checking
drug concentration, and it is used by pharmaceutical companies, toxicologists, and
pharmacologists. The basic principle of chromatography is the separation of mixtures
based on the speed of movement through a medium. After the sample goes through the
medium, a detector will measure the fluorescence, or the wavelength emitted by each of
the analytes, which is quantified. These tests are confirmed using standards and controls
and quantified using calibration curves from these standards. The assay was based on
validated assays used by others and implemented by the African National Quality Control
Laboratories (Gaudin et al., 2009; Gu, Li, Melendez, & Weina, 2008). The separation of
the mixtures was achieved by using column (100 × 4.6 mm, 3μm) as a stationary phase
and a binary gradient using a liquid phase (aqueous phase) containing phosphate buffer at
pH 3 (10 mm) and acetonitrile. The liquid phase will move the solubilized drugs through
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the stationary phase, which allows the drugs to separate based on the chemical properties,
the partition coefficient between the drugs and the column bed. These processes and
methodology were validated and has been accepted by the USFDA as the guideline in
order to ensure its robustness, specificity, accuracy and precision are achieved (Geditz et
al., 2014; Houstoun et al., 2014). HPLC grade (>99%) artemether and lumefantrine were
be purchased from Fisher Scientific to create standards and quality controls (Fischer
Scientific, 2016). This dissolved in fixed volumes of 20% water and 80% acetate buffer
PH 4.5 (buffer A) to make the calibration standards. The concentrations were measured
in mg/ml. The tablets were also dissolved in 10mls buffer A. These were vortexed and
centrifuged at 3500 rpm for 5 mins. The supernatant was decanted into a 96 well filter
plate before he samples were analyzed. These samples also included standards and
controls per good lab practice based on the code of federal regulations title 21 (U. S.
Food and Drug Administration, 2016) and the Guidance for Industry, Analytical
Procedure and Methods Validation for Drugs and Biologics (U. S. Food and Drug
Administration, 2001).
Analysis Plan
After all the data is collected, and the samples have been evaluated, the data was
imported into the Statistical Package, SPSS version 21, for further analyzes. The data was
exported from the instrument and verified to maintain the integrity and validity of the
data. The data collected from analyzing the concentrations of artemether and
lumefantrine in the lab using the HPLC system was entered into the SPSS spreadsheet to
determine the correlation between the pharmacies and LCS. Generally, analysis was
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conducted using descriptive statistics. Categorical variables were described using
frequencies and the continuous variables were examined using means and standard
deviations (Table 7). Possible Relationships between categorical independent variables
was tested using cross-tabulations with Pearson’s χ2 (Table 7). Multiple linear
regressions will also be used to assess the associations between the variables. The
probability of the distribution of the concentration of artemether and lumefantrine
concentrations was described using histograms.
Table 7.
List of Variables and Analyses
Type of Variable

Descriptive

Covarian
ce

Concentration of artemether (mg/ml) in private pharmacies
in Cities
Concentration of artemether (mg/ml) in private Small towns
and villages

Means and
SDs
Means and
SDs
Means and
SDs
Means and
SDs
Means and
SDs
Means and
SDs
Means and
SDs
Means and
SDs
Means and
SDs
Means and
SDs

ANOVA
's
ANOVA
's
ANOVA
's
ANOVA
's
ANOVA
's
ANOVA
's
ANOVA
's
ANOVA
's
ANOVA
's
ANOVA
's

Concentration of artemether (mg/ml) in LCS in Cities
Concentration of artemether (mg/ml) in LCS in Small towns
and villages
Concentration artemether (mg/ml) in Wholesale stores
Concentration of lumefantrine (mg/ml) in private
pharmacies in Cities
Concentration of lumefantrine (mg/ml) in private Small
towns and villages
Concentration of lumefantrine (mg/ml) in LCS in Cities
Concentration of lumefantrine (mg/ml) in LCS in Small
towns and villages
Concentration lumefantrine (mg/ml) in Wholesale stores
Continued on next page
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Type of Variable
Cost of Drugs
Correlation between Cost of Drugs and
pharmacies in Cities
Correlation between Cost of Drugs and LCS in
Cities
Correlation between Cost of Drugs and
pharmacies in small towns/villages
Correlation between Cost of Drugs and LCS in
small towns/villages

Number (Percent) of counterfeit Drugs in Cities
Number (Percent) of counterfeit artemether in
Cities
Number (Percent) of counterfeit lumefantrine
Cities
Number (Percent) of Drugs with Correct
concentration in Cities
Number (Percent) correct lumefantrine
concentration in Cities
Number (Percent) correct artemether
concentration in Cities
Number (Percent) of counterfeit Drugs in all
Pharmacies
Number (Percent) of counterfeit artemether in all
Pharmacies
Number (Percent) of counterfeit lumefantrine all
Pharmacies
Number (Percent) of Drugs with Correct
concentration in all Pharmacies
Number (Percent) correct lumefantrine
concentration in all Pharmacies
Number (Percent) correct artemether
concentration in all Pharmacies
Number (Percent) of counterfeit Drugs in all LCS
Number (Percent) of counterfeit artemether in all
LCS
Continued on next page

Descriptive
Means and
SDs
Correlation
coefficient (r)
Correlation
coefficient (r)
Correlation
coefficient (r)
Correlation
coefficient (r)
Frequencies
Frequencies
Frequencies
Frequencies
Frequencies
Frequencies
Frequencies
Frequencies
Frequencies
Frequencies
Frequencies
Frequencies
Frequencies
Frequencies

Covariance

ANOVA's
ANOVA's
ANOVA's
ANOVA's
ANOVA's
Crosstabs With
Pearson’s χ2
Crosstabs With
Pearson’s χ2
Crosstabs With
Pearson’s χ2
Crosstabs With
Pearson’s χ2
Crosstabs With
Pearson’s χ2
Crosstabs With
Pearson’s χ2
Crosstabs With
Pearson’s χ2
Crosstabs With
Pearson’s χ2
Crosstabs With
Pearson’s χ2
Crosstabs With
Pearson’s χ2
Crosstabs With
Pearson’s χ2
Crosstabs With
Pearson’s χ2
Crosstabs With
Pearson’s χ2
Crosstabs With
Pearson’s χ2
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Type of Variable
Number (Percent) of counterfeit lumefantrine all
LCS
Number (Percent) of Drugs with Correct
concentration in all LCS
Number (Percent) correct lumefantrine
concentration in all LCS
Number (Percent) correct artemether
concentration in all LCS
Number (Percent) of counterfeit Drugs in whole
sale stores
Number (Percent) of counterfeit artemether in
whole sale stores
Number (Percent) of counterfeit lumefantrine in
whole sale stores
Number (Percent) of Drugs with Correct
concentration in whole sale stores
Number (Percent) correct lumefantrine
concentration in whole sale stores
Number (Percent) correct artemether
concentration in whole sale stores
Number (Percent) of counterfeit Drugs in Small
towns and villages
Number (Percent) of counterfeit artemether in
small towns and villages
Number (Percent) of counterfeit lumefantrine in
small towns and villages
Number (Percent) of Drugs with Correct
concentration in small towns and villages
Number (Percent) correct lumefantrine
concentration in small towns and villages
Number (Percent) correct artemether
concentration in small towns and villages
Number (Percent) of counterfeit Drugs in City
Pharmacies
Number (Percent) of counterfeit artemether in
City Pharmacies
Number (Percent) of counterfeit lumefantrine
City Pharmacies
Number (Percent) of Drugs with Correct
concentration in City Pharmacies
Continued on the next page

Descriptive
Frequencies
Frequencies
Frequencies
Frequencies
Frequencies
Frequencies
Frequencies
Frequencies
Frequencies
Frequencies
Frequencies
Frequencies
Frequencies
Frequencies
Frequencies
Frequencies
Frequencies
Frequencies
Frequencies
Frequencies

Covariance
Crosstabs With
Pearson’s χ2
Crosstabs With
Pearson’s χ2
Crosstabs With
Pearson’s χ2
Crosstabs With
Pearson’s χ2
Crosstabs With
Pearson’s χ2
Crosstabs With
Pearson’s χ2
Crosstabs With
Pearson’s χ2
Crosstabs With
Pearson’s χ2
Crosstabs With
Pearson’s χ2
Crosstabs With
Pearson’s χ2
Crosstabs With
Pearson’s χ2
Crosstabs With
Pearson’s χ2
Crosstabs With
Pearson’s χ2
Crosstabs With
Pearson’s χ2
Crosstabs With
Pearson’s χ2
Crosstabs With
Pearson’s χ2
Crosstabs With
Pearson’s χ2
Crosstabs With
Pearson’s χ2
Crosstabs With
Pearson’s χ2
Crosstabs With
Pearson’s χ2
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Type of Variable
Number (Percent) correct lumefantrine
concentration in City Pharmacies
Number (Percent) correct artemether
concentration in City Pharmacies
Number (Percent) of counterfeit Drugs in City
LCS
Number (Percent) of counterfeit artemether in
City LCS
Number (Percent) of counterfeit lumefantrine
City LCS
Number (Percent) of Drugs with Correct
concentration in City LCS
Number (Percent) correct lumefantrine
concentration in City LCS
Number (Percent) correct artemether
concentration in City LCS
Number (Percent) of counterfeit artemether in
government pharmacies
Number (Percent) of counterfeit lumefantrine
government pharmacies
Number (Percent) of Drugs with Correct
concentration in government pharmacies
Number (Percent) correct lumefantrine
concentration in government pharmacies
Number (Percent) correct artemether
concentration in government pharmacies

Descriptive
Frequencies
Frequencies
Frequencies
Frequencies
Frequencies
Frequencies
Frequencies
Frequencies
Frequencies
Frequencies
Frequencies
Frequencies
Frequencies

Covariance
Crosstabs With
Pearson’s χ2
Crosstabs With
Pearson’s χ2
Crosstabs With
Pearson’s χ2
Crosstabs With
Pearson’s χ2
Crosstabs With
Pearson’s χ2
Crosstabs With
Pearson’s χ2
Crosstabs With
Pearson’s χ2
Crosstabs With
Pearson’s χ2
Crosstabs With
Pearson’s χ2
Crosstabs With
Pearson’s χ2
Crosstabs With
Pearson’s χ2
Crosstabs With
Pearson’s χ2
Crosstabs With
Pearson’s χ2

Below is a summary of the research questions:
1) RQ1 - Is there a difference between the percentage of counterfeit medication
in pharmacies found in the cities and those found in the rural areas? Was
tested using Crosstabs with Pearson’s χ2.
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2) RQ2 - Is there a difference in the percentage of counterfeit drugs between
pharmacies and Licensed Chemical Sellers? Was tested using Crosstabs with
Pearson’s χ2.
3) RQ3 - Is there a significant difference in the percentage of counterfeit drugs
between those drugs imported and drugs locally manufactured? Was tested
using Crosstabs with Pearson’s χ2.
4) RQ4 – Is there a significant difference in the percentage of counterfeit drugs
between drugs with scratch codes and those without scratch codes? Was tested
using Crosstabs with Pearson’s χ2.
Threats to Validity
There is the need for an evidence of validity and reliability for the study
especially during interpretation phase (Trochim, 2006). Therefore, a very specific and
sensitive assay to ensure the data accuracy was used as well as using a logical approach
to explain the problem and any dependent resolution to the problem statement. One of
such methodologies is the use of Construct validity. Construct validity addresses whether
the results are what they are supposed to be for the research or if what was done was what
it was intended to do (Fowler, 2009). It deals with how the variables were
operationalized and if they are related to the theory of the study. This was prevented from
happening with the use a validated HPLC assay, which is also the assay used for similar
studies. Another problem is the possibility of Internal validity issues, which mainly deals
with how the experiment was conducted and if it has an effect on the outcome (Fowler,
2009). There could be a flaw in the study because if sample collection and allocation of
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variables is not performed correctly, this could lead to the wrong conclusions.
Consequently, it could raise questions about conclusion validity. With a power of .08
(80%), the goal is to reduce this possibility. Another threat to external validity is the fact
that the conclusions drawn from this study should hold for the whole country. The goals
are to use the correct statistics to prevent this from happening. A limitation of this study
is that it is not providing any relationship or possible cause and effect between the
variables (Creswell, 2007).
Ethical Procedures
Approval from the Walden University Institutional Review Boards (1-06-1500041987) was obtained prior to data collection. I will observe all research ethics during
the primary data collection of this research. I will follow the ethical principles of the
Belmont Report. The confidentiality of the pharmacies and LCS was protected by not
revealing their names when the data is being processed. Each store was given a unique
identification code, and this code will in a separate, secure location from the data files.
All data was kept under password protection. Because these drugs could cause harm to
the patients that buy them, any retail store that is found to have counterfeit drugs was
reported to the Ghana food and drug administration (GFDA). The GFDA for the quality
of all drugs distributed in Ghana. It has the right to prosecute and arrest perpetrators. It
has been on high alert due to the incidence suspected counterfeit drugs in the Ghanaian
market. It was my ethical duty to report any such occurrences especially because I will
have the quantitative evidence.
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Summary
This chapter focused on the use of quantitative experimental research
methodology in this research investigation. The rational of the study is to assess the
quality of antimalarial medication in Ghana by empirically comparing the actual amount
of active ingredients of the two most prescribed antimalarial drugs, artemether and
lumefantrine, to the intended or labelled amount. These drugs were purchased from retail
stores in Ghana from various towns and cities, and measured using a HPLC to compare
the actual versus expected concentrations. The various topics included in this chapter
were study design, rational, study variables, target population, sampling and sampling
procedures, eligibility criteria, research questions and hypothesis, study variables
description and instrumentation, determination of the concentration of artemether and
Lumefantrine, sampling, ethics and threats to validity. Included in this chapter is a
description of my statistical analysis of the data. In Chapter 4, the results the study was
processed and discussed.
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Chapter 4: Results
Introduction
The purpose of this quantitative study was to explore the extent of antimalarial
counterfeiting by looking at the percentage of ATMT and LMFT in drugs sold in retail
outlets in Ghana that is counterfeit. The following are the research questions of this
study:
RQ1 - Is there a difference between the percentage of counterfeit medication in
pharmacies found in the cities and those found in the rural areas?
Ho1: There is no significant difference between the percentages of counterfeit
medication in pharmacies found in the cities versus those found in the rural areas.
Ha1: There is a significant difference between the percentages of counterfeit
medication in pharmacies found in the cities versus those found in the rural areas.
RQ2 - Is there a difference in the percentage of counterfeit drugs between
pharmacies and Licensed Chemical Sellers?
Ho2: There is no significant difference in the percentage of counterfeit drugs
between pharmacies and Licensed Chemical Sellers.
Ha2: There is a significant difference in the percentage of counterfeit drugs
between pharmacies and Licensed Chemical Sellers.
RQ3 - Is there a significant difference in the percentage of counterfeit drugs
between those drugs imported and drugs locally manufactured?
Ho3: There is no significant difference in the percentage of counterfeit drugs
between those drugs imported versus drugs locally manufactured.
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Ha3: There is a difference in the percentage of counterfeit drugs between those
drugs imported versus drugs locally manufactured.
RQ4 – Is there a correlation between the MPedigree scratch-off panel on the
packaging and percent of counterfeit drugs?
Ho4: There is no significant difference between the MPedigree scratch-off panel
on the packaging and percent of counterfeit drugs.
Ha4: There is a significant difference between the MPedigree scratch-off panel on
the packaging and percent of counterfeit drugs.
In this chapter, I will present the results of the study and descriptive statistics of
each variable, relationships among variables, and analyses conducted to examine the
research questions and hypotheses. In this study, alpha was set to .05, which means that
p-values less than .05 were considered statistically significant.
Data Collection
Divergence in data collection from the research plan presented in Chapter 3 is
presented here in the results section. The timeframe for this data collection was from
February 4, 2016 to June 7, 2016. I went to Ghana to collect the samples from all over
the country based on what was described in Chapter 3. There were no issues with
quickly purchasing products from the outlets, as there was no reason for the outlets not to
sell the drugs. As mentioned in Chapter 3, stratified sampling was used to group and
sample the population of the town or city based populations. Simple random sampling
method was used for sample collection. The goal of the study was to have a power of .08
(80%), with a Cohen specification of a large effect size of 0.5 for pharmacies and
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medium effect size 0.3 for LCS. For each hypothesis, a 95% confidence with the alpha
level (type 1 error) set to 0.05 (5%) was assumed.
Out of the outlets and demographics, nearly all carried the medication except for
government hospitals, which will not sell the mediation without prescription. The total
number of outlets in this study was 145. Demographics of pharmacies and license
chemical sellers are shown in Table 8; a majority of the drugs were purchased from LCS.
Table 8.
Descriptive Statistics of Location of Outlets
Outlets
Big city pharmacies
Whole sale pharmacies
Small town pharmacies
Big city LCS
Small town LCS

Frequency
23
6
17
19
46

Percent
28.0
7.3
20.7
23.2
20.7

Analytical Results
The mobile phase was made up of an aqueous solution composed of 0.05%
Trifluoracetic Acid (TFA) and acetonitrile 40:60 (v/v), adjusted a pH to 3 and filtered
through 0.45 µ membrane filter and sonicated before use. Flow rate of mobile phase was
maintained at 1.5 ml/min. The column temperature maintained was ambient temperature.
The detection was carried out at 210nm. Injection volume 20 µl and total run time was
3.5 min. Column was Zorbax SB-CN HPLC column (150 × 4.6 mm, 3.5 μm, Agilent).
Pyrimethamine was used as an internal standard. An example of the chromatogram is
shown on Figure 5.

64

Figure 5. Example of Chromatogram obtained for 50 ug/ml of artemether and 50 ug/ml
of lumefantrine.
A calibration curve was calculated and fitted by 1/x weighted regression of the peak-area
ratios of peak height of drug to the peak height of the internal standard. The standard
used for the calibration were 0, 1, 5, 100, 500 and 1000 ug/ml. The quality control
samples were 1, 40, 80 and 800 ug/ml. The concentration of the artemether and
lumefantrine in the tablets were calculated using the linear curve and multiplied by 1000
to represent the 1:1000 dilution for each tablet. The final concentration was therefore in
mg/ml. The accuracy of the method was determined by using known concentrations of
standard after it had been added to fixed concentration of the preanalyzed tablet solution.
Percent recovery was calculated by using the peak area before and after the addition of
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the known standards. The recovery studies were performed in triplicate using standard
addition method based on 10%, 100%, 1000% level and after which the recovery was
calculated. Based on this, average recovery was 99.2% for artemether and 99.4
lumefantrine, which confirms accuracy of the assay. Since some of the tablets had
different amounts, all of them were standardized to 20mg/ml for artemether and 120
mg/ml for lumefantrine. Summary of the descriptive statistics of the samples is shown in
Table 9. On average the mean (SD) was 15.8 (5.5) and 102.5 (5.5) for all locations
except for wholesale stores that did not have counterfeit drugs.
Table 9
Descriptive Statistics of Drug Concentrations

Concentration of artemether (mg/ml)
Private pharmacies in cities
Wholesale stores
Private pharmacies in small towns
and villages
LCS in cities
LCS in small towns and villages
Concentration of lumefantrine (mg/ml)
Private pharmacies in cities
Wholesale stores
Private pharmacies in small towns
and villages
LCS in cities
LCS in small towns and villages

N

mean

sd

min

max

16
6

16.2
16.1

5.7
5.6

0
4.75

20
19

17

15.5

0.5

14.8

19

46
65

15.6
15.6

5.3
5.1

1
0

19.8
20.8

16
6

104.8
117.3

34.6
1.8

0
115

120
120

17

96.3

34.6

26

118.5

46
65

100.1
100.6

29.8
29.5

17.5
15.75

119
119.3

When the drugs were purchased the prices were also recorded to see if this could affect
the quality of these drug being purchased. Of the 150 drugs that were purchased, the
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mean (sd) was 8.0 (3.8) Ghana Cedis. (1 dollar on the average at the time of purchase
was equivalent to 3.7 Ghana Cedis). The summary is shown on Table 10.
Table 10
Summary of Cost for Purchasing the Drugs
Location
Big city pharmacies
Wholesale pharmacies
Small town pharmacies
Big city LCS
Small town LCS
Total

Mean
9.44
5.83
9.00
7.72
7.78
8.00

N
16
6
17
46
65
150

Std. Deviation
5.5
1.6
5.7
2.9
3.3
3.8

I next determined the definition of counterfeit drugs based on the concentration.
The nominal value for artemether and lumefantrine were 20mg/ml and 120mg/ml
respectively. Generally, FDA considers these drugs as counterfeit (substandard) if the
concentration is less than 20 % of the expected values. In this case, all concentrations
less than 16 ng/ml and 96 ng/ml of artemether and lumefantrine respectively were
considered. Table 11 shows a summary of counterfeit drugs based on the locations.
Table 11
Summary of Quality of all Drugs based on Location

Location
Big city pharmacies
Whole sale pharmacies
Small town pharmacies
Big city LCS
Small town LCS
Total

Counterfeit
Number
%
1
6.3
0
0.0
3
17.6
11
23.9
15
23.1
30
20.0

Non- counterfeit
Number
%
15
93.8
6
100.0
14
82.4
35
76.1
50
76.9
120
80.0
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Table 12.
Summary of Quality of artemether and lumefantrine on Outlet

Outlet
Population
Pharmacy
LCS

Counterfeit
number
%
30
20.0
4
10.3
26
23.4

Non- counterfeit
Number
%
120
80.0
35
89.7
85
76.6

Table 13.
Summary of Quality of artemether and lumefantrine based on Presence or Absence of
Scratch

Outlet
No-Scratch
Scratch

Counterfeit
number
%
30
34.5
0
0

Non- counterfeit
number
%
57
65.5
63
100

Table 14.
Summary of quality of artemether and lumefantrine only based on import or local
manufacture

Outlet
Local
Imported

Counterfeit
number
%
0
0
30
23.6

Non- counterfeit
number
%
23
100
97
76.4

Out of 150 drugs that were purchased, 30 (20%) of them were counterfeit. Small
town LCS had the highest percentage of counterfeit medication, while wholesale
pharmacies had no counterfeit medication. Comparing both drugs, the trends were
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exactly the same. Any tablet that had counterfeit lumefantrine also had counterfeit
artemether. Comparing pharmacies and LCS, LCS had more counterfeit drugs (about
14% more) than pharmacies (Tables 12). None of the locally manufactured medications
were counterfeit (Tables 14). All the counterfeit medications were imported drugs and
had no mPedigree scratch-off panels on them (Tables 13).
Analysis of Research Questions
A few steps were taken in the analysis of research: several initial democratic
variables were lumped (collapsed) to generate other relevant variables, nonparametric
Pearson’s Chi square (χ2) tests were the primary analysis used to test the hypotheses, and
other tests used linear regression to determine the correlation between the cost of
medication and the quality of medication.
RQ1 - Is there a difference between the percentage of counterfeit medication in
pharmacies found in the cities and those found in the rural areas?
Ho1: There is no significant difference between the percentages of counterfeit
medication in pharmacies found in the cities versus those found in the rural areas.
Ha1: There is a significant difference between the percentages of counterfeit
medication in pharmacies found in the cities versus those found in the rural areas.
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Based on the results below, the p value (0.512) is > 0.05, (Table 15) the null hypothesis
cannot be rejected. There is no significant difference (χ2 = 0.430, p = 0.512) between the
quantity of counterfeit medication in pharmacies found in the cities versus those found in
the rural areas.

Table 15
Comparing the Quality of Drugs in Cities versus Rural Areas

Pearson Chi-Square
Continuity Correctionb
Likelihood Ratio
Fisher’s Exact Test
Linear-by-Linear
Association
N of Valid Cases

Value

df

.430
.203
.433

1
1
1

.428

1

Asymp. Sig. Exact Sig. (2- Exact Sig. (1(2-sided)
sided)
sided)
.512
.652
.510
.545
.327
.513

150

RQ2 - Is there a difference in the percentage of counterfeit drugs between
pharmacies and Licensed Chemical Sellers?
Ho2: There is no significant difference in the percentage of counterfeit drugs
between pharmacies and Licensed Chemical Sellers.
Ha2: There is a significant difference in the percentage of counterfeit drugs
between pharmacies and Licensed Chemical Sellers.
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Based on the results below, the p value (0.077) is > 0.05, (Table 17) the null
hypothesis was not rejected. There is a no significant difference (χ2 = 3.127, p = 0.077)
between the quantity of counterfeit drugs from pharmacy versus LCS.

Table 16
Comparing the Quality of Drugs in Pharmacy Versus LCS

Pearson Chi-Square
Continuity Correctionb
Likelihood Ratio
Fisher's Exact Test
Linear-by-Linear
Association
N of Valid Cases

Value

df

3.127
2.358
3.484

1
1
1

3.106

1

Asymp. Sig. Exact Sig. (2- Exact Sig. (1(2-sided)
sided)
sided)
.077
.125
.062
.103
.057
.078

150

RQ3 - Is there a significant difference in the percentage of counterfeit drugs
between those drugs imported and drugs locally manufactured?
Ho3: There is no significant difference in the percentage of counterfeit drugs
between those drugs imported versus drugs locally manufactured.
Ha3: There is a difference in the percentage of counterfeit drugs between those
drugs imported versus drugs locally manufactured.
Based on the results below, the p value (0.009) is < 0.05, (Table 17) the null
hypothesis was rejected in lieu of the alternative hypothesis. There is a significant
difference (χ2 = 6.791, p = 0.009) between the quantity of counterfeit drugs from locally
made versus imported drugs.

71
Table 17
Comparing the Quality of Drugs in Locally Made Versus Imported
Value
Pearson Chi-Square
Continuity Correctionb
Likelihood Ratio
Fisher's Exact Test
Linear-by-Linear
Association
N of Valid Cases

Df

6.791
5.395
11.263
6.746

Asymp. Sig. Exact Sig. (2- Exact Sig. (1(2-sided)
sided)
sided)
1
.009
1
.020
1
.001
.008
.004
1
.009

150

RQ4 – Is there a correlation between the MPedigree scratch-off panel on the
packaging and percent of counterfeit drugs?
Ho4: There is no significant difference between the MPedigree scratch-off panel
on the packaging and percent of counterfeit drugs.
Ha4: There is a significant difference between the MPedigree scratch-off panel on
the packaging and percent of counterfeit drugs.
Based the results below, the p value (0.000) is < 0.05, (Table 18) the null hypothesis was
rejected in lieu of the alternative hypothesis. There is a significant difference (χ2 =
27.155, p = 0.000) between the quantity of counterfeit drugs from mPedigree scratch-off
panel boxes versus those that were not scratched.
Table 18
Comparing the Quality of Drugs based on Use of mPedigree Scratch-off Panel
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Value
Pearson Chi-Square
Continuity Correctionb
Likelihood Ratio
Fisher’s Exact Test
Linear-by-Linear
Association
N of Valid Cases

27.155
25.043
38.032
26.974

df

Asymp. Sig. Exact Sig. (2- Exact Sig. (1(2-sided)
sided)
sided)
1
.000
1
.000
1
.000
.000
.000
1
.000

150

Using multiple regression analysis, it was found that the kind of store (Beta = .027, p =
.714) and the location in a city or small town/village (Beta = -.021, p = .143) are not
predictors of the quality artemether. Checking the same for lumefantrine the kind of store
(Beta = -.008, p = .898) and the location (Beta = -.027, p = .682) were also not predictors
of the quality of drugs. For both artemether (Beta = -.521, p < .05) and lumefantrine (Beta
= -.639, p < .05) the origin of the drug (local or imported) predictors for drug quality. This
was also true for the present of mPedigree scratch-off panel on boxes. For both artemether
(Beta = -.110, p < .01) and lumefantrine (Beta = -.151, p < .023), having the scratch was a
predictor of the quality if the drugs. Regression results are shown on Table 19 and Table
20 for LMFT and ATMT respectively.
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Table 19.
Multiple linear regression results from comparing dependent and all independent
variables for lumefantrine
Model

Unstandardized Standardized
Coefficients Coefficients
B

Std.
Error
(Constant)
299.029 34.823
imported or Local
- 18.676
drug
181.569
1 Location Pham &LCS -1.949 15.139
Location City&Small
-5.522 13.468
Town/Village
Scratch
31.312 13.625
a. Dependent Variable: Lumefantrin_Mean

t

Sig.

Beta
8.587
-.639
9.722
-.008 -.129
-.027 -.410

.000
.000
.898
.682

.151 2.298 .023

95.0%
Confidence
Interval for B
Lower Upper
Bound Bound
230.204 367.855
218.481 144.657
-31.870 27.972
-32.141 21.098
4.384

58.241
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Table 20.
Multiple linear regression results from comparing dependent and all independent
variables for artemether

Model

Unstandardized
Coefficients
B

Standardized
Coefficients

t

Sig.

95.0%
Confidence
Interval for B
Lower Upper
Bound Bound
6.394 .000 30.149 57.129

Beta

43.639

Std.
Error
6.825

-26.192

3.661

-.521

.000 -33.427 -18.957
7.155

.806

2.967

.020

.272

.786 -5.058

6.671

-.493

2.640

-.014

-.187 .852 -5.710

4.725

4.020

2.670

.110

1.505 .134 -1.258

9.298

(Constant)
imported or Local drug
LocationPham&LCS
LocationCity&SmallTownVillage
Scratch
a. Dependent Variable: Artemether_Mean

The cost of each of these drugs were recorded. A correlation analysis was performed to
check if there was c relation between the cost of drug and the quality of the drug. Cost of
drug and the quality or he drug were correlated for both (Kedell’s: artemether r= .243, p
<0.05 and Spearman’s: artemether r= .298, p <0.05) and lumefantrine (Kedell’s:
artemether r= .190, p <0.05 and Spearman’s: r= .258 p <0. Results for correlation
analysis is on Table 19 and Table 20 for artemether and lumefantrine respectively.
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Table 21.
Correlation results from comparing cot of drugs and artemether concentration

Correlation
Coefficient
Price_in_GHS
Sig. (2-tailed)
Kendall’s
N
tau_b
Correlation
Artemether_Mean
Coefficient
actual
Sig. (2-tailed)
N
Correlation
Coefficient
Price_in_GHS
Sig. (2-tailed)
N
Spearman's rho
Correlation
Artemether_Mean
Coefficient
actual
Sig. (2-tailed)
N
**. Correlation is significant at the 0.01 level (2-tailed).

Price_in_GHS Artemether_
Mean actual
1.000
.243**
.
150
.243**

.000
150
1.000

.000
150
1.000

.
150
.298**

.
150
.298**

.000
150
1.000

.000
150

.
150

Table 22.
Correlation results from comparing cost of drugs and lumefantrine concentration
Price_in_GH Lumefantrin_
S
Mean actual
Correlation
1.000
.190**
Coefficient
Price_in_GHS
Sig. (2-tailed)
.
.002
N
150
150
Kendall's tau_b
**
Correlation
.190
1.000
Lumefantrin_Mean
Coefficient
actual
Sig. (2-tailed)
.002
.
N
150
150
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Correlation
Coefficient
Price_in_GHS
Sig. (2-tailed)
N
Spearman's rho
Correlation
Lumefantrin_Mean
Coefficient
actual
Sig. (2-tailed)
N
**. Correlation is significant at the 0.01 level (2-tailed).

1.000

.258**

.
150
.258**

.001
150
1.000

.001
150

.
150

Conclusions
Pearson Chi-Square analyses were conducted to examine relationships among
variables. These tests were conducted to investigate the quality of antimalarial
medication. Overall, results revealed that about 20% of the antimalarial medications
tested were counterfeit. Even though the percent of counterfeit medication in LCS was
higher than pharmacies, this was not statistically significant. The same applies to
differences between cities and small towns/villages, this was not statistically significant.
Statistically significant differences were found between imported and locally made
drugs. The results form comparing drugs with mPedigree scratch-off panel boxes versus
drugs those without were similar. Cost of the drug was also correlated with the quality of
the drug. The implications of these findings as well as suggestions will be discussed in
Chapter 5.
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Chapter 5: Discussion, Conclusions, and Recommendations
Introduction
The main goal of this quantitative study was to explore the extent of antimalarial
counterfeit medication by looking at the quantities of ATMT and LMFT sold in retail
outlets in Ghana that is counterfeit. Fake and substandard drugs need to be addressed due
to the threats to patients: failure to provide effective treatments, adulteration with toxic
chemicals, and substandard drugs that can lead the parasites to become resistant to the
medications (Attaran et al., 2012). The amount of ATMT and LMFT purchased from
retail outlets in Ghana was determined using validated analytical methods and compared
to the expected amounts. Overall, results revealed about 20% of drugs purchased were
counterfeit. The findings and conclusions of this study are discussed in the following
section.
Interpretation of the Findings
Difference between Locations
The first set of findings about counterfeit medication relates to the following
question: Is there a difference between the percentage of counterfeit medication in drug
stores found in cities and those found in the rural areas? Results revealed no statistical
difference between cities and rural areas (see Table 18). Despite this study’s results,
according to Gasmelseid (2016), not only is there a huge variation between geographic
regions when it comes to the prevalence of counterfeit medications, variations can also
exist between rural and urban centers. There is no difference in Ghana based on this data
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likely because these medications in the rural areas are purchased from the cities, and they
may have the same sources.
Difference between Pharmacies and LCS
The next set of findings about counterfeit medication relates to the following
question: Is there a difference in the percentage of counterfeit drugs between pharmacies
and licensed chemical sellers? Results show some difference between pharmacies and
LCS, with pharmacies exhibiting higher quality, but this difference was not statistically
significant (Table 19). Because of the structure of pharmacies compared to LCS, it was
expected to have a significantly higher. LCS are usually independently owned by
nonpharmacists, usually by pharmacy technicians at best, and no training is required to
obtain a license (FHI360, 2013). This means LCS are prone to illegal practices such as
sale of prescription medication, which is illegal but overlooked by authorities in Ghana.
The fact that there is no significant difference also shows that they likely purchase from
similar sources.
Difference between Imported and Locally Manufactured Drugs
The next finding relates to the following question: Is there a significant difference
in the percentage of counterfeit drugs between those drugs imported and drugs locally
manufactured? Results revealed that there is a statistical difference between the qualities
of drugs that were manufactured locally compared to import ones (Table 20). Ghana has
a well-established and developing pharmaceutical manufacturing base, and this report
provides profiles of six of the major Ghana pharmaceutical manufacturers. The profiles
provide some interesting contrasts in manufacturing strategy against the background of
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many common constraints for local pharmaceutical manufacturing development in
Ghana. Locally manufactured drugs make about 30% of drugs in the Ghanaian
pharmaceutical market. A majority (70%) of medication used in Ghana is mostly
imported and they are mostly Southeastern Asia (India and China). There is generally the
presumption that I imported goods including medication have higher quality that locally
manufactured goods. The locally manufactured medication also tends to be higher in
prices. Unfortunately, most of the 750 million counterfeit drugs seized in Africa by
World Customs Organization (WCO) since 2012 were from India and China (Barbiere,
2017). It is also important to mention that cost of the drug was also found correlated with
the quality of the drug.
Effect of mPedigree Scratch-off Panel
The final finding relates to the following question: Is there a correlation between
the mPedigree scratch-off panel on the packaging and percent of counterfeit drugs?
Results revealed that there is a statistical difference between the qualities of drugs with
the mPedigree scratch-off panel compared to those without (Table 21). This was the
largest decider of the quality of drug as all counterfeit medication found in this study had
no mPedigree scratch-off panel. This was expected because drugs with this mPedigree
scratch-off panel are supposed to be good quality and from the manufacturer.
Findings in Relation to Theoretical Framework
The use of explanatory theory in the study is supported by the results of the study
that 20% of drugs are counterfeit, which empirically defined the scope of the problem.
Using receptor occupancy theory, the concentration of the drugs was determined to assess
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the quality of the drugs. The concentration of the drugs correlated with the amount of
drug that will occupy the receptors which correlated with response/efficacy. The total
efficacy can only be achieved if all the receptors needed to destroy the plasmodium
parasite are occupied. In this case 20% of the drugs will not achieve total efficacy. It
also means that there will be no difference in efficacy if we compared location (cities and
rural) and LCS versus pharmacies. On the other hand, there will be differences in
efficacy between imported versus locally manufactured and the presence versus absence
of the mPedigree scratch-off panel.
Limitations of the Study
Limitations for this study include generalization and whether the results are valid
and reliable. Examining two antimalarial medications in Ghana may not provide a
complete representation of all antimalarial medication in Africa. One way to overcome
this in future research is to study other medications and include other countries in the sub
region. Another limitation of this study is that the study may not capture all possible
outlets. The data was based on data for a country that lacks good data collection systems.
The presence of possible illegal outlets is also a limitation, because these are not being
counted. Some of these were solved by making sure the data collection process is done
based on statistics, using random sampling and other research methods.
Recommendations
A recommendation for future researchers is to include different countries and
different experimental designs as a part of their studies. A recommendation to healthcare
personnel, government, and patients is to be aware of the 20% counterfeit antimalarial
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mediation in the system and eliminate it. From this study, all drugs with the mPedigree
scratch-off panel were of good quality, leading to a recommendation to promote only
drugs with a mPedigree scratch-off panel. Another recommendation is to promote locally
manufactured medication; all drugs imported from India and China should be scrutinized
to make sure they are not counterfeit. The government will need to hold companies who
are selling and marketing counterfeit medication accountable to deter others.
Implications
The results from this research can help the Ghana standard boards, the Ghana
health service, other stakeholders, and policymakers understand the scope of counterfeit
antimalarial medication in Ghana. Government/nongovernment organizations and the
society at large will benefit from this information. With a better understanding of how
much antimalarial medication is counterfeit in Ghana, organizations can create
interventions to minimize the effects of counterfeit antimalarial medication in Ghana.
Some of the findings may also have a positive impact on public health. The results show
that there is no difference between the quality of the medication between cities and rural
areas of the country, which implies they likely have similar sources. The results also
inform the public on the quality of medication based on mPedigree scratch-off panels;
none of the drugs in this study with mPedigree scratch-off panel were counterfeit, which
indicates the public should purchase only drugs with mPedigree scratch-off panel and
locally manufactured instead of imported medication. With these results, there can be
advocacy to get the government to provide subsidies to local companies to help drive the
cost down, which will make the medication more affordable comparable to the cost of
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buying imported drugs. Finally, the names of the companies with the fake/counterfeit
drugs will be given to the authorities for further investigation, so the sources of these
counterfeit drugs can be cut off.
Conclusions
The outcomes, the results, and the lessons learned from the results of this study
have many implications that can lead to positive social change (e.g., awareness of ways
to acquire quality medication, understanding of the distribution of counterfeit medication
and possible reduction, or eradication of the sources of these counterfeit medications) not
only in Ghana but also in other sub-Saharan African countries. The results from this
study can be used by all stakeholders to effectively control the amount of counterfeit
medication in the Ghana which is a public health issue. For example, the findings of this
study suggest drugs with mPedigree scratch-off panel are likely to be of high quality, so
stakeholders should work together to create awareness and to educate people about how
this works and why it is important to purchase only drugs with these panels. Results also
reveal that all counterfeit drugs were imported. Therefore, stakeholders should also work
together to make locally manufactured drugs more assessable and encourage/educate the
public to use locally manufactured drugs.
Malaria is still an epidemic in many parts of the world and it still affects millions
of people worldwide. Malaria can be treated with several drugs and these drugs work
well if used appropriately and contain the right amounts of the active ingredient. In this
study, 20% of these drugs were found to be counterfeit. This study begins to help us
address the counterfeit problem by empirically finding out the distribution of the
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counterfeit medication. Knowing the distribution will help with the initiation of
programs to help address this problem.
In summary, in the attempt to eradicate of malaria, secondary prevention plays a
pivotal role, which means that people infected by the parasite need to be treated quickly
and efficaciously to curb the spread of the disease. All medications therefore need to
have the correct active ingredients, the correct regimens adhered to, and the correct use
for the right disease. Tackling the issue of counterfeit medication and making quality
drugs assessable is very important aspect of this process.
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